date,ticker,pct_change_prev_close,day_percent_change,max_day_percent_change,source,title,description,url,same_or_prev
9/28/15,HRTX,-23.5,-24.18831169,0.032467532,bw,Heron Therapeutics Announces Oral Presentation of Data from Completed Phase 3 MAGIC Study for SUSTOL¬Æ at the ASCO Breast Cancer Symposium,"Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today announced...",http://www.businesswire.com/news/home/20150928005483/en/Heron-Therapeutics-Announces-Oral-Presentation-of-Data-from-Completed-Phase-3-MAGIC-Study-for-SUSTOL%C2%AE-at-the-ASCO-Breast-Cancer-Symposium,same
10/20/15,NEOS,-32.9,-25.32934132,0,bw,Neos Therapeutics Cotempla XR-ODT FDA Update,"Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company with a late‚Äêstage pipeline of innovative extended-release (XR) product candidates for the treatment of attention deficit hyperactivity d...",http://www.businesswire.com/news/home/20151019006538/en/Neos-Therapeutics-Cotempla-XR-ODT-FDA-Update,prev
10/27/15,AGIO,24.8,26.46875,27.328125,gnw,Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors at AACR-NCI-EORTC,"CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the...",https://www.globenewswire.com/news-release/2015/10/26/780126/31990/en/Agios-to-Present-Clinical-Data-from-Ongoing-AG-120-Phase-1-Trial-in-Advanced-Solid-Tumors-at-AACR-NCI-EORTC.html,prev
11/5/15,EYEG,58.1,56.27376426,90.11406844,gnw,EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients,"WALTHAM, Mass., Nov. 5, 2015 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (""EyeGate"" or the ""Company""), a specialty pharmaceutical company that focuses on developing and...",https://www.globenewswire.com/news-release/2015/11/05/784089/33326/en/EyeGate-Announces-Interim-Data-From-Phase-1b-2a-Clinical-Trial-of-Iontophoretic-EGP-437-Ophthalmic-Solution-in-Macular-Edema-Patients.html,same
3/1/16,PTCT,-30.5,-26.58730159,1.71957672,bw,"Robbins Arroyo LLP Is Investigating the Officers and Directors of PTC Therapeutics, Inc. (PTCT) on Behalf of Shareholders","Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQGS: PTCT) violated federal securities laws by issuing materially...",http://www.businesswire.com/news/home/20160229007033/en/Robbins-Arroyo-LLP-Is-Investigating-the-Officers-and-Directors-of-PTC-Therapeutics-Inc.-PTCT-on-Behalf-of-Shareholders,prev
3/2/16,ADXS,26.6,20.09646302,20.41800643,gnw,Advaxis Study in Head and Neck Cancer Selected for Late-Breaking Poster at the American Association for Cancer Research Annual Meeting,"PRINCETON, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that data from a Phase 2...",https://www.globenewswire.com/news-release/2016/03/02/816132/29755/en/Advaxis-Study-in-Head-and-Neck-Cancer-Selected-for-Late-Breaking-Poster-at-the-American-Association-for-Cancer-Research-Annual-Meeting.html,same
5/11/16,CCXI,53.8,52.3178808,60.77152318,gnw,"ChemoCentryx to Host R&D Day on May 18, 2016","MOUNTAIN VIEW, Calif., May 11, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat...",https://www.globenewswire.com/news-release/2016/05/11/838884/19219/en/ChemoCentryx-to-Host-R-D-Day-on-May-18-2016.html,same
8/1/16,APVO,-22.1,-32.63403263,0.932400932,bw,Aptevo Therapeutics Secures $35 Million Term Loan Agreement,"Aptevo Therapeutics Inc. (‚ÄúAptevo‚Äù; ‚Äúthe Company‚Äù) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today that it has reached agreemen...",http://www.businesswire.com/news/home/20160801005439/en/Aptevo-Therapeutics-Secures-35-Million-Term-Loan-Agreement,same
8/1/16,APVO,-22.1,-32.63403263,0.932400932,bw,Aptevo Therapeutics Completes Separation from Emergent BioSolutions,"Aptevo Therapeutics Inc. (‚ÄúAptevo‚Äù) (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, announced today the completion of its separation from Emerg...",http://www.businesswire.com/news/home/20160801005403/en/Aptevo-Therapeutics-Completes-Separation-from-Emergent-BioSolutions,same
8/8/16,FATE,22.7,21.59624413,23.94366197,gnw,Fate Therapeutics Announces $10.3 Million Common Stock Private Placement,"SAN DIEGO, Aug. 08, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer...",https://www.globenewswire.com/news-release/2016/08/08/862343/24675/en/Fate-Therapeutics-Announces-10-3-Million-Common-Stock-Private-Placement.html,same
8/23/16,CLVS,27.2,25.84699454,36.44535519,bw,FDA Accepts Clovis Oncology‚Äôs New Drug Application for Rucaparib for Priority Review for the Treatment of Advanced Mutant BRCA Ovarian Cancer,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted Clovis‚Äô New Drug Application (NDA) for accelerated approval of rucaparib and granted...",http://www.businesswire.com/news/home/20160823006191/en/FDA-Accepts-Clovis-Oncology%E2%80%99s-New-Drug-Application-for-Rucaparib-for-Priority-Review-for-the-Treatment-of-Advanced-Mutant-BRCA-Ovarian-Cancer,same
9/19/16,SRPT,73.9,69.87157237,95.00173551,bw,"Sarepta Therapeutics Announces FDA Accelerated Approval of EXONDYS 51‚Ñ¢ (eteplirsen) injection, an Exon Skipping Therapy to Treat Duchenne Muscular Dystrophy (DMD) Patients Amenable to Skipping Exon 51","Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXO...",http://www.businesswire.com/news/home/20160919006292/en/Sarepta-Therapeutics-Announces-FDA-Accelerated-Approval-of-EXONDYS-51%E2%84%A2-eteplirsen-injection-an-Exon-Skipping-Therapy-to-Treat-Duchenne-Muscular-Dystrophy-DMD-Patients-Amenable-to-Skipping-Exon-51,same
1/10/17,SRPT,21.2,20.51526718,25.1908397,bw,Sarepta Therapeutics Enters into Research Agreement and Option Agreement with Nationwide Children‚Äôs Hospital for Microdystrophin Gene Therapy Program,"Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered a research and option agreement with Nationwide Children‚Äô...",http://www.businesswire.com/news/home/20170110005558/en/Sarepta-Therapeutics-Enters-into-Research-Agreement-and-Option-Agreement-with-Nationwide-Children%E2%80%99s-Hospital-for-Microdystrophin-Gene-Therapy-Program,same
1/10/17,SRPT,21.2,20.51526718,25.1908397,bw,Sarepta Therapeutics Enters into License Agreement with Nationwide Children‚Äôs Hospital for Galgt2 Gene Therapy Program,"Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial stage developer of innovative RNA-targeted therapeutics, today announced it has entered an exclusive license agreement with Nationwide Children‚Äôs...",http://www.businesswire.com/news/home/20170110005563/en/Sarepta-Therapeutics-Enters-into-License-Agreement-with-Nationwide-Children%E2%80%99s-Hospital-for-Galgt2-Gene-Therapy-Program,same
2/7/17,EYES,78.1,78.06451613,82.58064516,bw,"Second Sight Medical Products, Inc. Announces Record Date, Subscription Pricing, Expiration Date for Rights Offering and Effectiveness of Its Registration Statement","Second Sight Medical Products, Inc. (Nasdaq:EYES), (""Second Sight"" or ""the Company""), a developer, manufacturer and marketer of implantable visual prosthetics to provide some useful vision to blind pa...",http://www.businesswire.com/news/home/20170206005534/en/Second-Sight-Medical-Products-Inc.-Announces-Record-Date-Subscription-Pricing-Expiration-Date-for-Rights-Offering-and-Effectiveness-of-Its-Registration-Statement,prev
3/16/17,MCRB,37.1,27.1,33.15,bw,Seres Therapeutics to Initiate New SER-109 Clinical Study,"Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today announced plans to initiate a new SER-109 Phase 2 clinical study (ECOSPOR III) in patients with multip...",http://www.businesswire.com/news/home/20170316005279/en/Seres-Therapeutics-to-Initiate-New-SER-109-Clinical-Study,same
3/31/17,ACOR,-21.5,-21.34831461,2.247191011,bw,U.S. District Court Issues Decision to Invalidate Four AMPYRA Patents; Company Will Appeal Ruling,"Acorda Therapeutics, Inc. (Nasdaq: ACOR ) today announced that the United States District Court for the District of Delaware upheld U.S. Patent No. 5,540,938 (the ‚Äò938 patent), which pertains to the f...",http://www.businesswire.com/news/home/20170331005631/en/U.S.-District-Court-Issues-Decision-to-Invalidate-Four-AMPYRA-Patents-Company-Will-Appeal-Ruling,same
3/31/17,DRNA,25.9,23.63636364,23.63636364,bw,Dicerna Secures $70 Million in Convertible Preferred Stock Financing,"Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the ‚ÄúCompany‚Äù), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purcha...",http://www.businesswire.com/news/home/20170330006188/en/Dicerna-Secures-70-Million-in-Convertible-Preferred-Stock-Financing,prev
5/2/17,AEZS,-33.3,-25,3.333333333,bw,Aeterna Zentaris Announces that ZoptEC Phase 3 Clinical Study of Zoptrex‚Ñ¢ Did Not Achieve its Primary Endpoint,"Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the ‚ÄúCompany‚Äù) today announced that the ZoptEC Phase 3 clinical study of Zoptrex‚Ñ¢ (zoptarelin doxorubicin) in women with locally advanced, recurrent or...",http://www.businesswire.com/news/home/20170501005409/en/Aeterna-Zentaris-Announces-that-ZoptEC-Phase-3-Clinical-Study-of-Zoptrex%E2%84%A2-Did-Not-Achieve-its-Primary-Endpoint,prev
5/17/17,SNDX,44.6,25.74074074,41.99074074,gnw,Syndax Pharmaceuticals Announces Advancement of ENCORE 601 in Non-Small Cell Lung Cancer Patients with Disease Progression on or After PD-1 Therapies,"WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (""Syndax,"" the ""Company"" or ""we"") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...",https://www.globenewswire.com/news-release/2017/05/16/986671/0/en/Syndax-Pharmaceuticals-Announces-Advancement-of-ENCORE-601-in-Non-Small-Cell-Lung-Cancer-Patients-with-Disease-Progression-on-or-After-PD-1-Therapies.html,prev
5/18/17,GLYC,98.7,36.27075351,47.89272031,bw,"GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML","GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the release of abstracts containing new data from the ongoing Phase 2 clinical trial of its product candidate GMI-1271, an E-selectin antagonist, in...",http://www.businesswire.com/news/home/20170518005294/en/GlycoMimetics-Announces-High-Overall-Response-Rates-Low-Induction-Mortality%C2%A0Promising-Initial-Survival-Outcomes-and-Supportive-Biomarker-Data-from-Phase-12-Trial-of-GMI-1271-in-AML,same
5/18/17,GLYC,98.7,36.27075351,47.89272031,bw,GlycoMimetics‚Äô GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia,"GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for treatment of adult relapsed/refractory acute myeloi...",http://www.businesswire.com/news/home/20170517006262/en/GlycoMimetics%E2%80%99-GMI-1271-Receives-FDA-Breakthrough-Therapy-Designation-for-Adult-RelapsedRefractory-Acute-Myeloid-Leukemia,prev
7/19/17,AEZS,129.4,50.96774194,80.64516129,bw,"NDA for Macrilen‚Ñ¢ for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date","Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the ‚ÄúCompany‚Äù) today announced that it has been notified by the U.S. Food and Drug Administration (‚ÄúFDA‚Äù), that the Company‚Äôs New Drug Application (‚ÄúND...",http://www.businesswire.com/news/home/20170718006321/en/NDA-for-Macrilen%E2%84%A2-for-the-Evaluation-of-Growth-Hormone-Deficiency-in-Adults-Granted-December-30-2017-PDUFA-Date,prev
7/26/17,EGRX,-23.8,-24.02846975,2.320284698,bw,Eagle Pharmaceuticals Receives Complete Response Letter from FDA on RYANODEX for Exertional Heat Stroke Application,"Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (‚ÄúEagle‚Äù or ‚Äúthe Company‚Äù) announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) regarding its 505(...",http://www.businesswire.com/news/home/20170726005970/en/Eagle-Pharmaceuticals-Receives-Complete-Response-Letter-from-FDA-on-RYANODEX-for-Exertional-Heat-Stroke-Application,same
7/26/17,EGRX,-23.8,-24.02846975,2.320284698,bw,"Eagle Pharmaceuticals, Inc. Issues Statement Regarding RYANODEX Application PDUFA Date for Exertional Heat Stroke","Eagle Pharmaceuticals, Inc. (‚ÄúEagle‚Äù or ‚Äúthe Company‚Äù) (Nasdaq: EGRX) today issued a statement that it has not yet received correspondence from the US Food and Drug Administration (FDA) regarding its...",http://www.businesswire.com/news/home/20170725005895/en/Eagle-Pharmaceuticals-Inc.-Issues-Statement-Regarding-RYANODEX-Application-PDUFA-Date-for-Exertional-Heat-Stroke,prev
8/15/17,TNDM,37.3,37.27272727,42.72727273,bw,Tandem Diabetes Care Begins Enrollment in Pivotal Trial for First Touchscreen Insulin Pump with Predictive Low Glucose Suspend (PLGS),"Tandem Diabetes Care¬Æ, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced enrollment of the first pati...",http://www.businesswire.com/news/home/20170815005421/en/Tandem-Diabetes-Care-Begins-Enrollment-in-Pivotal-Trial-for-First-Touchscreen-Insulin-Pump-with-Predictive-Low-Glucose-Suspend-PLGS,same
9/7/17,NLNK,74.6,42.25941423,51.46443515,bw,Updated Data for Indoximod Plus KEYTRUDA¬Æ (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma,"NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics‚Äô IDO pathway inhibitor, in combination with the PD-1 path...",http://www.businesswire.com/news/home/20170907005441/en/Updated-Data-for-Indoximod-Plus-KEYTRUDA%C2%AE-pembrolizumab-Demonstrate-Improvement-of-Response-Rate-for-Patients-with-Advanced-Melanoma,same
9/8/17,NLNK,29.9,26.4853257,38.1531854,bw,Updated Data for Indoximod Plus KEYTRUDA¬Æ (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma,"NewLink Genetics Corporation (NASDAQ: NLNK) today announced updated data from the ongoing Phase 2 NLG2103 study of indoximod, NewLink Genetics‚Äô IDO pathway inhibitor, in combination with the PD-1 path...",http://www.businesswire.com/news/home/20170907005441/en/Updated-Data-for-Indoximod-Plus-KEYTRUDA%C2%AE-pembrolizumab-Demonstrate-Improvement-of-Response-Rate-for-Patients-with-Advanced-Melanoma,prev
11/2/17,DRNA,28.2,20.5,31.49833333,bw,Boehringer Ingelheim and Dicerna Announce Collaboration to Develop Novel Treatments for Chronic Liver Diseases including Nonalcoholic Steatohepatitis (NASH),"Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreem...",http://www.businesswire.com/news/home/20171102005456/en/Boehringer-Ingelheim-and-Dicerna-Announce-Collaboration-to-Develop-Novel-Treatments-for-Chronic-Liver-Diseases-including-Nonalcoholic-Steatohepatitis-NASH,same
11/7/17,FPRX,-40.9,-28.16666667,8.833333333,bw,Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data,"Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, announced today that it will...",http://www.businesswire.com/news/home/20171107006912/en/Five-Prime-Therapeutics-to-Host-Conference-Call-on-November-8-to-Review-Cabiralizumab-Phase-1a1b-Data,same
11/10/17,HAIR,24.8,24.82638889,28.05555556,gnw,"Restoration Robotics, Inc. to Participate in Two International Medical Meetings Focused on the Asia-Pacific Market","SAN JOSE, Calif., Nov. 10, 2017 (GLOBE NEWSWIRE) -- Restoration Robotics, Inc. (NASDAQ:HAIR) announced today that the Company will participate in two international medical meetings focused on the...",https://www.globenewswire.com/news-release/2017/11/10/1184811/0/en/Restoration-Robotics-Inc-to-Participate-in-Two-International-Medical-Meetings-Focused-on-the-Asia-Pacific-Market.html,same
12/19/17,TYME,20.6,21.42857143,38.33333333,gnw,Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium,"NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its...",https://www.globenewswire.com/news-release/2017/12/19/1266109/0/en/Tyme-to-Present-Efficacy-Data-on-SM-88-in-Pancreatic-Cancer-at-2018-ASCO-Gastrointestinal-Cancers-Symposium.html,same
12/20/17,TYME,37.3,34.35700576,34.35700576,gnw,Tyme to Present Efficacy Data on SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium,"NEW YORK, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that efficacy data from its...",https://www.globenewswire.com/news-release/2017/12/19/1266109/0/en/Tyme-to-Present-Efficacy-Data-on-SM-88-in-Pancreatic-Cancer-at-2018-ASCO-Gastrointestinal-Cancers-Symposium.html,prev
12/28/17,EARS,33.1,23.8,32,gnw,"Auris Medical News Release - Auris Medical to Provide Update on Its AM-111 Hearing Loss Program on Thursday, January 4, 2018","Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...",https://www.globenewswire.com/news-release/2017/12/28/1275751/0/en/Auris-Medical-News-Release-Auris-Medical-to-Provide-Update-on-Its-AM-111-Hearing-Loss-Program-on-Thursday-January-4-2018.html,same
1/5/18,KALA,-29.3,-23.40625,0,bw,Kala Pharmaceuticals Announces Topline Results for Two Phase 3 Trials (STRIDE 1 and STRIDE 2) of KPI-121 0.25% in Dry Eye Disease,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced topline results from its two Phase 3 clinical trials, STRIDE 1 and STRIDE 2 (STRIDE - Short Term Relief In Dry Eye), evaluating the safety and...",http://www.businesswire.com/news/home/20180105005184/en/Kala-Pharmaceuticals-Announces-Topline-Results-for-Two-Phase-3-Trials-STRIDE-1-and-STRIDE-2-of-KPI-121-0.25-in-Dry-Eye-Disease,same
1/5/18,KALA,-29.3,-23.40625,0,bw,Kala Pharmaceuticals Announces New Drug Application for INVELTYSTM (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration,"Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) tech...",http://www.businesswire.com/news/home/20180105005187/en/Kala-Pharmaceuticals-Announces-New-Drug-Application-for-INVELTYSTM-KPI-121-1-Has-Been-Accepted-for-Review-by-the-U.S.-Food-and-Drug-Administration,same
2/13/18,KDMN,-21.3,-28.78504673,0.934579439,bw,Kadmon Announces Positive Topline Results from Phase 2 Study of KD025 in Idiopathic Pulmonary Fibrosis,"Kadmon Holdings, Inc. (NYSE:KDMN) today announced topline results from an ongoing Phase 2 clinical trial evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with i...",http://www.businesswire.com/news/home/20180212006192/en/Kadmon-Announces-Positive-Topline-Results-from-Phase-2-Study-of-KD025-in-Idiopathic-Pulmonary-Fibrosis,prev
4/10/18,VTVT,-78.1,-29.26732673,0,bw,vTv Therapeutics Announces Topline Results from the First STEADFAST Phase 3 Study Evaluating Azeliragon in People with Mild Alzheimer‚Äôs Disease,"vTv Therapeutics, Inc. (vTv) (Nasdaq:VTVT) today announced that results from Part A of the Company‚Äôs Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer‚Äô...",http://www.businesswire.com/news/home/20180409006413/en/vTv-Therapeutics-Announces-Topline-Results-from-the-First-STEADFAST-Phase-3-Study-Evaluating-Azeliragon-in-People-with-Mild-Alzheimer%E2%80%99s-Disease,prev
6/4/18,DCPH,47.9,42.15213358,42.5974026,bw,Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock,"Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced that it has commenced a propose...",http://www.businesswire.com/news/home/20180604006385/en/Deciphera-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock,same
8/7/18,GEMP,-50.5,-24.53222453,1.455301455,gnw,Gemphire Announces Amended and Restated Gemcabene License Agreement with Pfizer Inc.,"LIVONIA, Mich., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for...",https://www.globenewswire.com/news-release/2018/08/06/1547658/0/en/Gemphire-Announces-Amended-and-Restated-Gemcabene-License-Agreement-with-Pfizer-Inc.html,prev
8/15/18,PTIE,77.5,51.53846154,80,gnw,Pain Therapeutics Awarded $3.2 Million NIH Grant to Study Alzheimer‚Äôs Disease,"‚Äì NIH Grant will Support Clinical Testing of PTI-125 ‚Äì ‚Äì Initiation of Phase II Study Expected Q4 2018 ‚Äì AUSTIN, Texas, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a...",https://www.globenewswire.com/news-release/2018/08/15/1552288/0/en/Pain-Therapeutics-Awarded-3-2-Million-NIH-Grant-to-Study-Alzheimer-s-Disease.html,same
8/22/18,AMDA,29.1,27.63157895,44.73684211,gnw,Amedica Announces Successful Completion of First Valeo¬Æ C+CSC with Lumen Interbody Fusion Surgery,"SALT LAKE CITY, Aug. 21, 2018 (GLOBE NEWSWIRE) -- Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications,...",https://www.globenewswire.com/news-release/2018/08/21/1554575/30038/en/Amedica-Announces-Successful-Completion-of-First-Valeo-C-CSC-with-Lumen-Interbody-Fusion-Surgery.html,prev
8/23/18,OBLN,52,33,43,gnw,Obalon Therapeutics to Raise $10 Million in Private Placement,"SAN DIEGO, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN) a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled...",https://www.globenewswire.com/news-release/2018/08/23/1555881/0/en/Obalon-Therapeutics-to-Raise-10-Million-in-Private-Placement.html,same
8/29/18,KOOL,21.6,50,56.66666667,gnw,Cesca Therapeutics Announces Poster Presentation at the 4th Annual CAR-TCR Summit,"RANCHO CORDOVA, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies,...",https://www.globenewswire.com/news-release/2018/08/29/1558281/21307/en/Cesca-Therapeutics-Announces-Poster-Presentation-at-the-4th-Annual-CAR-TCR-Summit.html,same
9/10/18,ACOR,-24.5,-25.17985612,0.179856115,bw,U.S. Court of Appeals for the Federal Circuit Upholds District Court‚Äôs Decision to Invalidate AMPYRA¬Æ (dalfampridine) Patents,"Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the United States Court of Appeals for the Federal Circuit, by a 2-1 vote, has upheld the United States District Court for the District of...",http://www.businesswire.com/news/home/20180910005687/en/U.S.-Court-of-Appeals-for-the-Federal-Circuit-Upholds-District-Court%E2%80%99s-Decision-to-Invalidate-AMPYRA%C2%AE-dalfampridine-Patents,same
9/20/18,ACAD,26.6,25.72368421,26.25,bw,FDA Issues Statement Reaffirming the Positive Benefit-Risk Profile of NUPLAZID¬Æ (pimavanserin) for Patients with Hallucinations and Delusions Associated with Parkinson‚Äôs Disease Psychosis,ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that the FDA has completed a postmarketing review and issued a clear statement reaffirming the positive benefit-risk profile of NUPLAZID (pim...,http://www.businesswire.com/news/home/20180920005948/en/FDA-Issues-Statement-Reaffirming-the-Positive-Benefit-Risk-Profile-of-NUPLAZID%C2%AE-pimavanserin-for-Patients-with-Hallucinations-and-Delusions-Associated-with-Parkinson%E2%80%99s-Disease-Psychosis,same
9/24/18,SPPI,-22.7,-22.44131455,0.610328638,bw,Spectrum Pharmaceuticals Announces Release of Updated Poziotinib Data From MD Anderson Phase 2 Study in Non-Small Cell Lung Cancer Patients,"Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announc...",http://www.businesswire.com/news/home/20180924005695/en/Spectrum-Pharmaceuticals-Announces-Release-of-Updated-Poziotinib-Data-From-MD-Anderson-Phase-2-Study-in-Non-Small-Cell-Lung-Cancer-Patients,same
9/25/18,TGTX,-44.3,-21.96969697,1.515151515,gnw,TG Therapeutics Announces Update Regarding UNITY-CLL Phase 3 Trial,"NEW YORK, Sept. 25, 2018 (GLOBE NEWSWIRE) -- TG Therapeutics (NASDAQ: TGTX) today announced that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review...",https://www.globenewswire.com/news-release/2018/09/25/1575546/8790/en/TG-Therapeutics-Announces-Update-Regarding-UNITY-CLL-Phase-3-Trial.html,same
9/26/18,VLRX,32,29.41176471,37.25490196,gnw,Valeritas Begins Medical Device Registration Process in China for Its V-Go¬Æ Wearable Insulin Delivery Device,"BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go¬Æ Wearable Insulin Delivery device, a simple, all-in-one,...",https://www.globenewswire.com/news-release/2018/09/26/1576414/0/en/Valeritas-Begins-Medical-Device-Registration-Process-in-China-for-Its-V-Go-Wearable-Insulin-Delivery-Device.html,same
9/27/18,VLRX,21.2,36.75213675,41.88034188,gnw,Valeritas Begins Medical Device Registration Process in China for Its V-Go¬Æ Wearable Insulin Delivery Device,"BRIDGEWATER, N.J., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go¬Æ Wearable Insulin Delivery device, a simple, all-in-one,...",https://www.globenewswire.com/news-release/2018/09/26/1576414/0/en/Valeritas-Begins-Medical-Device-Registration-Process-in-China-for-Its-V-Go-Wearable-Insulin-Delivery-Device.html,prev
10/1/18,OMER,-42.8,-43.11328443,1.329665852,bw,Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy,Omeros Corporation (NASDAQ: OMER) today announced positive data from the company‚Äôs ongoing Phase 2 clinical trial of OMS721 for the treatment of renal diseases. The data are from study patients with i...,http://www.businesswire.com/news/home/20181001005895/en/Omeros-Corporation-Announces-Additional-Positive-Data-for-OMS721-in-IgA-Nephropathy,same
10/1/18,NTGN,35.2,32.91139241,34.90563867,gnw,Neon Therapeutics to Present at the Society for Immunotherapy of Cancer 33rd Annual Meeting,"CAMBRIDGE, Mass. , Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced...",https://www.globenewswire.com/news-release/2018/10/01/1588222/0/en/Neon-Therapeutics-to-Present-at-the-Society-for-Immunotherapy-of-Cancer-33rd-Annual-Meeting.html,same
10/1/18,NTGN,35.2,32.91139241,34.90563867,gnw,"Neon Therapeutics Congratulates Founder James P. Allison, Ph.D., for 2018 Nobel Prize in Physiology or Medicine ","Award Recognizes Achievements in Cancer Immunotherapy CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing...",https://www.globenewswire.com/news-release/2018/10/01/1587886/0/en/Neon-Therapeutics-Congratulates-Founder-James-P-Allison-Ph-D-for-2018-Nobel-Prize-in-Physiology-or-Medicine.html,same
10/12/18,EARS,44.1,26.04501608,28.61736334,gnw,"Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018","Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology...",https://www.globenewswire.com/news-release/2018/10/12/1620480/0/en/Auris-Medical-to-provide-update-on-intranasal-betahistine-program-on-Wednesday-October-17-2018.html,same
11/12/18,CNCE,-21.6,-23.18486882,0,bw,Concert Pharmaceuticals Reports Positive CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata,"Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced interim topline results from the first two cohorts of its Phase 2a trial evaluating its investigational treatment CTP-543 in patients with...",http://www.businesswire.com/news/home/20181112005162/en/Concert-Pharmaceuticals-Reports-Positive-CTP-543-Results-from-Interim-Analysis-of-Phase-2a-Trial-in-Patients-with-Alopecia-Areata,same
11/26/18,TYME,30.2,27.27272727,36.36363636,gnw,"Tyme Technologies, Inc. to Present at the Piper Jaffray Healthcare Conference on November 28th","NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today...",https://www.globenewswire.com/news-release/2018/11/26/1656913/0/en/Tyme-Technologies-Inc-to-Present-at-the-Piper-Jaffray-Healthcare-Conference-on-November-28th.html,same
11/26/18,TYME,30.2,27.27272727,36.36363636,gnw,Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium,"NEW YORK, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will...",https://www.globenewswire.com/news-release/2018/11/26/1656548/0/en/Tyme-Announces-the-Presentation-of-Clinical-Abstracts-at-the-2019-Gastrointestinal-Cancers-Symposium.html,same
12/7/18,DMAC,-47,-22.5,6.25,gnw,DIAMEDICA ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING AND NASDAQ LISTING,"MINNEAPOLIS, Dec. 07, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (‚ÄúDiaMedica‚Äù) (NASDAQ:DMAC) (TSX‚ÄëV:DMA), a clinical stage biopharmaceutical company, announced today the pricing of its...",https://www.globenewswire.com/news-release/2018/12/07/1663697/0/en/DIAMEDICA-ANNOUNCES-PRICING-OF-INITIAL-PUBLIC-OFFERING-AND-NASDAQ-LISTING.html,same
12/27/18,BTAI,80.9,32.12121212,50.60606061,gnw,BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation,"NEW HAVEN, Conn., Dec. 27, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (‚ÄúBTI‚Äù or ‚ÄúCompany‚Äù) (Nasdaq: BTAI), today announced that the U.S. FDA has granted Fast Track Designation for its...",https://www.globenewswire.com/news-release/2018/12/27/1678491/0/en/BioXcel-Therapeutics-Receives-FDA-Fast-Track-Designation-for-BXCL501-for-Acute-Treatment-of-Agitation.html,same
1/4/19,TMDI,26.7,25.75757576,33.46212121,bw,Titan Medical Completes Build of Its Next-Generation Single-Port Robotic Surgical System,"Titan Medical Inc. (TSX: TMD) (Nasdaq: TMDI) (‚ÄúTitan‚Äù or the ‚ÄúCompany‚Äù), a medical device company focused on the design and development of a robotic surgical system for application in minimally invasi...",http://www.businesswire.com/news/home/20190103005374/en/Titan-Medical-Completes-Build-of-Its-Next-Generation-Single-Port-Robotic-Surgical-System,prev
1/31/19,AVEO,-60.5,-34.63551402,2.803738318,bw,AVEO Oncology Announces NDA Timing Update,AVEO Oncology (NASDAQ: AVEO) today announced that it has accepted the recommendation of the U.S. Food and Drug Administration (FDA) not to submit a New Drug Application (NDA) for tivozanib (FOTIVDA¬Æ)...,http://www.businesswire.com/news/home/20190131005509/en/AVEO-Oncology-Announces-NDA-Timing-Update,same
1/31/19,NVUS,41.2,38.2636656,45.9807074,bw,Novus Therapeutics Advances OP0201 Development Program Across Several Clinical Trials,"Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today provided updates on sev...",http://www.businesswire.com/news/home/20190130005201/en/Novus-Therapeutics-Advances-OP0201-Development-Program-Across-Several-Clinical-Trials,prev
3/5/19,RTTR,35.1,29.43079865,36.7848213,gnw,Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance,"Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (‚ÄúRitter Pharmaceuticals‚Äù or the ‚ÄúCompany‚Äù), a...",https://www.globenewswire.com/news-release/2019/03/05/1748047/0/en/Ritter-Pharmaceuticals-Completes-Enrollment-in-Pivotal-Phase-3-Clinical-Trial-of-RP-G28-in-Patients-with-Lactose-Intolerance.html,same
3/7/19,SEEL,96.1,29.91452992,47.00854701,gnw,Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference,"NEW YORK, March 06, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, announced today that they will webcast their presentation at the...",https://www.globenewswire.com/news-release/2019/03/06/1748757/14295/en/Seelos-Therapeutics-to-Webcast-Presentation-at-the-39th-Annual-Cowen-Health-Care-Conference-and-Participate-in-the-31st-Annual-ROTH-Conference.html,prev
3/8/19,ALT,-36.6,-20.66115703,3.305785124,gnw,Altimmune Announces $14 million Registered Direct Offering,"GAITHERSBURG, Md., March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two...",https://www.globenewswire.com/news-release/2019/03/08/1750641/0/en/Altimmune-Announces-14-million-Registered-Direct-Offering.html,same
3/13/19,CNAT,25.7,23.5042735,29.05982906,gnw,Conatus Late-breaker Oral Presentation at EASL Meeting to Detail Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension,"SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International...",https://www.globenewswire.com/news-release/2019/03/13/1752549/27069/en/Conatus-Late-breaker-Oral-Presentation-at-EASL-Meeting-to-Detail-Results-of-ENCORE-PH-Phase-2b-Clinical-Trial-in-Patients-with-NASH-Cirrhosis-and-Severe-Portal-Hypertension.html,same
3/13/19,AKTX,224.2,180.952381,192.3809524,gnw,Positive FDA Meeting Outlines Path Ahead for Akari Therapeutics‚Äôs Coversin in Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA),"HSCT-TMA trial in pediatric patients expected to start Q4 2019 following recent FDA feedback NEW YORK and LONDON, March 13, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a...",https://www.globenewswire.com/news-release/2019/03/13/1752502/0/en/Positive-FDA-Meeting-Outlines-Path-Ahead-for-Akari-Therapeutics-s-Coversin-in-Hematopoietic-Stem-Cell-Transplant-Related-Thrombotic-Microangiopathy-HSCT-TMA.html,same
3/14/19,ATOS,368.2,52.04301075,58.92473118,gnw,Atossa Genetics Announces FDA Approval of Oral Endoxifen for ‚ÄúExpanded Access‚Äù as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient,"SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...",https://www.globenewswire.com/news-release/2019/03/14/1753171/0/en/Atossa-Genetics-Announces-FDA-Approval-of-Oral-Endoxifen-for-Expanded-Access-as-Post-Mastectomy-Treatment-for-a-U-S-Breast-Cancer-Patient.html,same
3/15/19,ATOS,-50.4,-34.51492537,5.223880597,gnw,Atossa Genetics Announces FDA Approval of Oral Endoxifen for ‚ÄúExpanded Access‚Äù as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient,"SEATTLE, March 14, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer...",https://www.globenewswire.com/news-release/2019/03/14/1753171/0/en/Atossa-Genetics-Announces-FDA-Approval-of-Oral-Endoxifen-for-Expanded-Access-as-Post-Mastectomy-Treatment-for-a-U-S-Breast-Cancer-Patient.html,prev
3/22/19,LXRX,-21.9,-21.6182048,1.643489254,gnw,"Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes","THE WOODLANDS, Texas, March 22, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that management will conduct a conference call and live webcast today, Friday,...",https://www.globenewswire.com/news-release/2019/03/22/1759503/0/en/Lexicon-Pharmaceuticals-to-Host-Conference-Call-and-Webcast-Today-March-22-2019-to-Provide-a-Regulatory-Update-on-Sotagliflozin-in-Type-1-Diabetes.html,same
3/25/19,NK,32.5,21.01449275,35.47826087,bw,NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants and Options in Support of NK‚Äôs Natural Killer Cell Strategic Vision Beyond Check Point Immunotherapy,"NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Patrick Soon-Shiong, MD, the company‚Äôs Chairman & CEO, on March 21, 2019, exer...",http://www.businesswire.com/news/home/20190325005242/en/NantKwest-Chairman-CEO-Dr.-Patrick-Soon-Shiong-Exercises-39-Million-in-Warrants-and-Options-in-Support-of-NK%E2%80%99s-Natural-Killer-Cell-Strategic-Vision-Beyond-Check-Point-Immunotherapy,same
4/1/19,AVEO,35.3,38.75,43.75,bw,AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML,"AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO‚Äôs potent hepatocyte growth factor (HGF) inhibitory...",http://www.businesswire.com/news/home/20190401005861/en/AVEO-and-Biodesix-Announce-Positive-Results-from-Phase-Ib-Ficlatuzumab-Cytarabine-Trial-in-Patients-with-Relapsed-and-Refractory-AML,same
4/2/19,CYCN,-36.6,-25.76844262,7.581967213,bw,Ironwood Pharmaceuticals Completes Separation of Cyclerion Therapeutics and Becomes a Gastrointestinal (GI)-focused Healthcare Company,"Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that it has completed the tax-free spin-off of its soluble guanylate cyclase (sGC) business, Cyclerion T...",http://www.businesswire.com/news/home/20190401005676/en/Ironwood-Pharmaceuticals-Completes-Separation-of-Cyclerion-Therapeutics-and-Becomes-a-Gastrointestinal-GI--focused-Healthcare-Company,prev
4/2/19,AVEO,42.3,26.4,48,bw,AVEO and Biodesix Announce Positive Results from Phase Ib Ficlatuzumab-Cytarabine Trial in Patients with Relapsed and Refractory AML,"AVEO Oncology (NASDAQ:AVEO) and Biodesix, Inc. today announced results from an investigator-sponsored Phase Ib expansion cohort of ficlatuzumab, AVEO‚Äôs potent hepatocyte growth factor (HGF) inhibitory...",http://www.businesswire.com/news/home/20190401005861/en/AVEO-and-Biodesix-Announce-Positive-Results-from-Phase-Ib-Ficlatuzumab-Cytarabine-Trial-in-Patients-with-Relapsed-and-Refractory-AML,prev
4/15/19,CNAT,-34.4,-33.87603306,0,gnw,Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension,"SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) announced today that the company‚Äôs late-breaker oral presentation at The International Liver Congress‚Ñ¢ 2019,...",https://www.globenewswire.com/news-release/2019/04/15/1803885/27069/en/Conatus-Late-breaker-Oral-Presentation-at-EASL-Meeting-Details-Results-of-ENCORE-PH-Phase-2b-Clinical-Trial-in-Patients-with-NASH-Cirrhosis-and-Severe-Portal-Hypertension.html,same
4/22/19,NVUS,-30,-27.91262136,0,bw,Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials,"Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced results from...",http://www.businesswire.com/news/home/20190422005248/en/Novus-Therapeutics-Announces-Results-of-Two-Single-Dose-OP0201-Phase-1-Clinical-Trials,same
5/22/19,VLRX,-26.3,-46.01941748,0.970873786,gnw,Valeritas‚Äô V-Go¬Æ Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population,"BRIDGEWATER, N.J., May 22, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go¬Æ Wearable Insulin Delivery device, today announced...",https://www.globenewswire.com/news-release/2019/05/22/1840653/0/en/Valeritas-V-Go-Demonstrates-Positive-Impact-in-Diabetes-Quality-Performance-Measures-in-an-Older-Adult-Population.html,same
5/29/19,VLRX,37.8,34.94809689,52.24913495,gnw,"American Diabetes Association Includes ‚ÄúDisposable Patch-Like Device,‚Äù such as V-Go¬Æ from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019","BRIDGEWATER, N.J., May 28, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go¬Æ Wearable Insulin Delivery device, today announced the...",https://www.globenewswire.com/news-release/2019/05/28/1851985/0/en/American-Diabetes-Association-Includes-Disposable-Patch-Like-Device-such-as-V-Go-from-Valeritas-in-the-ADA-Standards-of-Medical-Care-in-Diabetes-2019.html,prev
5/29/19,TTPH,26.8,24.70098804,33.90535621,bw,Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society,"Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announ...",http://www.businesswire.com/news/home/20190529005078/en/Tetraphase-Pharmaceuticals-to-Present-Data-at-the-39th-Annual-Meeting-of-the-Surgical-Infection-Society,same
6/3/19,NK,25.2,25.24271845,33.98058252,bw,NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference,"NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong and Company management will be participating in the Jeffer...",http://www.businesswire.com/news/home/20190603005273/en/NantKwest-to-Present-and-Provide-Update-at-Upcoming-Jefferies-2019-Annual-Healthcare-Conference,same
6/25/19,ACER,-78.6,-22.84644195,0,gnw,Acer Therapeutics Receives Complete Response Letter from U.S. FDA for use of EDSIVO‚Ñ¢ (celiprolol) in vEDS Patients,"NEWTON, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...",https://www.globenewswire.com/news-release/2019/06/25/1873784/0/en/Acer-Therapeutics-Receives-Complete-Response-Letter-from-U-S-FDA-for-use-of-EDSIVO-celiprolol-in-vEDS-Patients.html,same
7/8/19,ADVM,22.5,22.53289474,23.02631579,gnw,Adverum Biotechnologies to Present Data at Upcoming Conferences,"MENLO PARK, Calif., July 08, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,...",https://www.globenewswire.com/news-release/2019/07/08/1879380/32452/en/Adverum-Biotechnologies-to-Present-Data-at-Upcoming-Conferences.html,same
7/23/19,SLRX,23,25.62770563,28.13852814,gnw,Salarius Pharmaceuticals Enrolls First Patient in a Phase 1 Clinical Study of its Novel Inhibitor Targeting Epigenetics in Patients with Advanced Solid Tumors,"HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced it has...",https://www.globenewswire.com/news-release/2019/07/22/1885742/0/en/Salarius-Pharmaceuticals-Enrolls-First-Patient-in-a-Phase-1-Clinical-Study-of-its-Novel-Inhibitor-Targeting-Epigenetics-in-Patients-with-Advanced-Solid-Tumors.html,prev
7/23/19,SLRX,23,25.62770563,28.13852814,gnw,Salarius Pharmaceuticals Announces Closing of Strategic Merger with Flex Pharma,"HOUSTON, July 22, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that Salarius...",https://www.globenewswire.com/news-release/2019/07/22/1885713/0/en/Salarius-Pharmaceuticals-Announces-Closing-of-Strategic-Merger-with-Flex-Pharma.html,prev
7/24/19,PSTI,-25.1,-21.11111111,0,gnw,Pluristem Announces One-for-Ten Reverse Split of its Common Shares,"HAIFA, Israel, July 24, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...",https://www.globenewswire.com/news-release/2019/07/24/1886961/11974/en/Pluristem-Announces-One-for-Ten-Reverse-Split-of-its-Common-Shares.html,same
8/9/19,ASRT,-45.9,-46.09929078,2.836879433,gnw,Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021,"LAKE FOREST, Ill., Aug. 09, 2019 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (NASDAQ: ASRT) (‚ÄúAssertio‚Äù) today announced it has entered into separate, privately negotiated exchange agreements...",https://www.globenewswire.com/news-release/2019/08/09/1899968/0/en/Assertio-Therapeutics-Announces-Exchange-Offer-of-200-Million-of-its-Currently-Outstanding-2-50-Convertible-Notes-Due-2021.html,same
8/27/19,NVTR,46.2,23.66863905,38.46153846,gnw,Nuvectra¬Æ Exploring Strategic Options to Enhance Shareholder Value,"PLANO, Texas, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR), a neurostimulation medical device company, today announced that its Board of Directors has decided to explore...",https://www.globenewswire.com/news-release/2019/08/26/1906735/0/en/Nuvectra-Exploring-Strategic-Options-to-Enhance-Shareholder-Value.html,prev
8/28/19,OTLK,21.2,22.13740458,41.22137405,gnw,Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference,"CRANBURY, N.J., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the ‚ÄúCompany‚Äù) today announced that it is scheduled to participate in the H.C. Wainwright 21st Annual...",https://www.globenewswire.com/news-release/2019/08/27/1907054/0/en/Outlook-Therapeutics-to-Present-at-the-H-C-Wainwright-21st-Annual-Healthcare-Conference.html,prev
9/3/19,ABEO,90.9,49.23857868,69.035533,gnw,Abeona Therapeutics Announces Strategic Review,"NEW YORK and CLEVELAND, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it has retained Jefferies...",https://www.globenewswire.com/news-release/2019/09/03/1910080/0/en/Abeona-Therapeutics-Announces-Strategic-Review.html,same
9/10/19,LXRX,21.1,22.85714286,25.71428571,gnw,Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting,"THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that clinical data for ZynquistaTM (sotagliflozin) will be presented at the...",https://www.globenewswire.com/news-release/2019/09/10/1913800/0/en/Lexicon-Pharmaceuticals-to-Present-Sotagliflozin-Clinical-Data-at-the-European-Association-for-the-Study-of-Diabetes-55th-Annual-Meeting.html,same
9/10/19,LXRX,21.1,22.85714286,25.71428571,gnw,Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement With Sanofi,"THE WOODLANDS, Texas, Sept. 10, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the termination of its alliance with Sanofi for the development and...",https://www.globenewswire.com/news-release/2019/09/10/1913802/0/en/Lexicon-Pharmaceuticals-Announces-Termination-of-Alliance-and-Settlement-With-Sanofi.html,same
9/23/19,PSTV,-49.5,-72.63513514,8.108108108,gnw,"Plus Therapeutics, Inc. Announces Pricing Of $15 Million Underwritten Public Offering","AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering (the ‚ÄúOffering‚Äù) of 3,000,000...",https://www.globenewswire.com/news-release/2019/09/23/1919404/0/en/Plus-Therapeutics-Inc-Announces-Pricing-Of-15-Million-Underwritten-Public-Offering.html,same
9/23/19,PSTV,-49.5,-72.63513514,8.108108108,gnw,Plus Therapeutics to Receive $4.6MM Reimbursement Payment,"AUSTIN, Texas, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù) today announced that it received notice from the U.S. Department of Health and Human Services...",https://www.globenewswire.com/news-release/2019/09/23/1918967/0/en/Plus-Therapeutics-to-Receive-4-6MM-Reimbursement-Payment.html,same
9/25/19,TMDI,-42.7,-23.87096774,2.580645161,bw,Titan Medical Continues to Market Offering of Units,"Titan Medical Inc. (‚ÄúTitan‚Äù or the ‚ÄúCompany‚Äù) (TSX:TMD) (Nasdaq:TMDI), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in...",http://www.businesswire.com/news/home/20190924006063/en/Titan-Medical-Continues-to-Market-Offering-of-Units,prev
9/27/19,TTPH,21.4,28.76404494,38.65168539,bw,Tetraphase Pharmaceuticals Announces Reverse Stock Split,"Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threateni...",http://www.businesswire.com/news/home/20190926005007/en/Tetraphase-Pharmaceuticals-Announces-Reverse-Stock-Split,prev
10/2/19,SVRA,-58.5,-25.89928058,0,bw,Savara Announces FDA Response From Type C Meeting on Molgradex for aPAP Development Program,"Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the response from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the Molgradex development prog...",http://www.businesswire.com/news/home/20191002005287/en/Savara-Announces-FDA-Response-From-Type-C-Meeting-on-Molgradex-for-aPAP-Development-Program,same
10/3/19,CBIO,24.6,21.17647059,23.1372549,gnw,Catalyst Biosciences Provides DalcA Phase 2b Trial Update,"SOUTH SAN FRANCISCO, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today provided an update on enrollment in its Phase 2b study of dalcinonacog alfa (DalcA), a...",https://www.globenewswire.com/news-release/2019/10/03/1924663/35555/en/Catalyst-Biosciences-Provides-DalcA-Phase-2b-Trial-Update.html,same
10/7/19,SRNE,-25.5,-28.51405623,16.86746988,gnw,Sorrento Therapeutics Announces $25 Million Registered Direct Offering,"SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ‚ÄúSorrento‚Äù), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...",https://www.globenewswire.com/news-release/2019/10/07/1926068/0/en/Sorrento-Therapeutics-Announces-25-Million-Registered-Direct-Offering.html,same
10/7/19,RTTR,50,40.74074074,64.81481482,gnw,Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives,"LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (‚ÄúRitter Pharmaceuticals‚Äù or the ‚ÄúCompany‚Äù), a developer of innovative therapeutic products that...",https://www.globenewswire.com/news-release/2019/10/07/1925862/0/en/Ritter-Pharmaceuticals-Engages-Financial-Advisor-to-Explore-Strategic-Alternatives.html,same
10/8/19,RTTR,-28.7,-28.68421053,0,gnw,Ritter Pharmaceuticals Engages Financial Advisor to Explore Strategic Alternatives,"LOS ANGELES, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (‚ÄúRitter Pharmaceuticals‚Äù or the ‚ÄúCompany‚Äù), a developer of innovative therapeutic products that...",https://www.globenewswire.com/news-release/2019/10/07/1925862/0/en/Ritter-Pharmaceuticals-Engages-Financial-Advisor-to-Explore-Strategic-Alternatives.html,prev
10/18/19,DERM,25.8,23.44827586,46.89655172,bw,Dermira Presents Data From Phase 2b Study of Lebrikizumab in Patients With Atopic Dermatitis at Fall Clinical Dermatology Conference,"Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living...",http://www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-From-Phase-2b-Study-of-Lebrikizumab-in-Patients-With-Atopic-Dermatitis-at-Fall-Clinical-Dermatology-Conference,prev
10/30/19,ELGX,-21.2,-20.68965517,4.827586207,bw,"Endologix, Inc. Comments on Recent FDA Update on Type III Endoleaks with AFX¬Æ Endovascular AAA System","Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced a response to the U.S. Food and Drug Administration (FDA) update regarding Type...",http://www.businesswire.com/news/home/20191029005394/en/Endologix-Inc.-Comments-on-Recent-FDA-Update-on-Type-III-Endoleaks-with-AFX%C2%AE-Endovascular-AAA-System,prev
11/1/19,TNXP,22.9,26.73781772,35.86574919,gnw,Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split,"NEW YORK, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect...",https://www.globenewswire.com/news-release/2019/10/31/1939026/28908/en/Tonix-Pharmaceuticals-Announces-1-for-10-Reverse-Stock-Split.html,prev
11/6/19,SNSS,-23,-22.77227723,0,gnw,Sunesis Pharmaceuticals Announces Presentation at 61st American Society of Hematology Annual Meeting,"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a poster presentation at the 61st American Society of Hematology (ASH)...",https://www.globenewswire.com/news-release/2019/11/06/1942296/14761/en/Sunesis-Pharmaceuticals-Announces-Presentation-at-61st-American-Society-of-Hematology-Annual-Meeting.html,same
11/13/19,DFFN,-54.7,-58.5,8.333333333,gnw,Diffusion Pharmaceuticals Announces $4.0 Million Public Offering,"CHARLOTTESVILLE, Va., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (‚ÄúDiffusion‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biotechnology company developing new treatments...",https://www.globenewswire.com/news-release/2019/11/13/1946432/0/en/Diffusion-Pharmaceuticals-Announces-4-0-Million-Public-Offering.html,same
11/13/19,NVTR,-83.8,-35.29580701,10.48248133,gnw,Nuvectra¬Æ Continuing to Support Current Patients with the Algovita¬Æ Implant as Company Voluntarily Files for Chapter 11,"PLANO, Texas, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ: NVTR) (‚ÄúNuvectra‚Äù or the ‚ÄúCompany‚Äù), a neurostimulation medical device company, today announced that it has elected to...",https://www.globenewswire.com/news-release/2019/11/12/1945976/0/en/Nuvectra-Continuing-to-Support-Current-Patients-with-the-Algovita-Implant-as-Company-Voluntarily-Files-for-Chapter-11.html,prev
11/18/19,NVIV,-37.5,-33.30864198,0,bw,InVivo Therapeutics Announces Proposed Public Offering of Common Stock,"InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) today announced that it has commenced a proposed public offering of shares of its common stock, par value $0.00001 per share. The proposed public offe...",http://www.businesswire.com/news/home/20191118005283/en/InVivo-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock,same
11/18/19,KRTX,443,195.3846154,207.6923077,bw,Karuna Therapeutics Announces Proposed Public Offering of Common Stock,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005866/en/Karuna-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock,same
11/18/19,KRTX,443,195.3846154,207.6923077,bw,Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005243/en/Karuna-Therapeutics-Announces-KarXT-Met-Primary-Endpoint-in-Phase-2-Clinical-Trial-of-Acute-Psychosis-in-Patients-with-Schizophrenia,same
11/18/19,KRTX,443,195.3846154,207.6923077,bw,Karuna Therapeutics Schedules Webcast and Conference Call to Announce Results from its Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191117005056/en/Karuna-Therapeutics-Schedules-Webcast-and-Conference-Call-to-Announce-Results-from-its-Phase-2-Clinical-Trial-of-KarXT-for-the-Treatment-of-Psychosis-in-Patients-with-Schizophrenia,prev
11/19/19,KRTX,29.2,38.30451757,69.54824317,bw,Karuna Therapeutics Announces Proposed Public Offering of Common Stock,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005866/en/Karuna-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock,prev
11/19/19,KRTX,29.2,38.30451757,69.54824317,bw,Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191118005243/en/Karuna-Therapeutics-Announces-KarXT-Met-Primary-Endpoint-in-Phase-2-Clinical-Trial-of-Acute-Psychosis-in-Patients-with-Schizophrenia,prev
11/21/19,KRTX,-27.2,-21.67669989,0.661205961,bw,Karuna Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock,"Karuna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and pote...",http://www.businesswire.com/news/home/20191120006025/en/Karuna-Therapeutics-Announces-Pricing-of-250-Million-Public-Offering-of-Common-Stock,prev
11/21/19,ONTX,-45.7,-64.23580786,28.44978166,gnw,"Onconova Therapeutics, Inc. Announces $11.0 Million Public Offering","NEWTOWN, Pa., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (‚ÄúOnconova‚Äù), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat...",https://www.globenewswire.com/news-release/2019/11/21/1950988/0/en/Onconova-Therapeutics-Inc-Announces-11-0-Million-Public-Offering.html,same
11/25/19,SRNE,94.4,41.36363636,45,gnw,"Sorrento Therapeutics, Inc. Received and Rejected Unsolicited All Cash Acquisition Proposal","SAN DIEGO, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, ""Sorrento"" or the ‚ÄúCompany‚Äù), confirmed today that on November 23, 2019, it received an unsolicited,...",https://www.globenewswire.com/news-release/2019/11/25/1951876/0/en/Sorrento-Therapeutics-Inc-Received-and-Rejected-Unsolicited-All-Cash-Acquisition-Proposal.html,same
11/26/19,CBAY,24.8,22.96296296,27.40740741,gnw,CymaBay Therapeutics Halts Clinical Development of Seladelpar,"NEWARK, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic...",https://www.globenewswire.com/news-release/2019/11/25/1951942/37067/en/CymaBay-Therapeutics-Halts-Clinical-Development-of-Seladelpar.html,prev
12/9/19,APTO,38.3,25.53191489,40.78014184,gnw,Aptose Presents New Preclinical CG-806 Data at the 2019 ASH Annual Meeting,"SAN DIEGO and TORONTO, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (‚ÄúAptose‚Äù) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting...",https://www.globenewswire.com/news-release/2019/12/09/1958050/35575/en/Aptose-Presents-New-Preclinical-CG-806-Data-at-the-2019-ASH-Annual-Meeting.html,same
12/10/19,ITRM,21.9,21.25,79.75,gnw,Iterum Therapeutics Announces Topline Results from Phase 3 Clinical Trial of Oral and IV Sulopenem for the Treatment of Complicated Intra-abdominal Infections,"DUBLIN, Ireland and CHICAGO, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing an oral and IV penem antibiotic...",https://www.globenewswire.com/news-release/2019/12/10/1958907/0/en/Iterum-Therapeutics-Announces-Topline-Results-from-Phase-3-Clinical-Trial-of-Oral-and-IV-Sulopenem-for-the-Treatment-of-Complicated-Intra-abdominal-Infections.html,same
12/11/19,MRNS,38,31.85185185,36.2962963,gnw,Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement,"RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (‚ÄúMarinus‚Äù or the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering of 28,000,000...",https://www.globenewswire.com/news-release/2019/12/11/1959362/32077/en/Corrected-Press-Release-Marinus-Pharmaceuticals-Announces-Pricing-of-65-Million-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html,same
12/11/19,MRNS,38,31.85185185,36.2962963,gnw,Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement,"RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (‚ÄúMarinus‚Äù or the ‚ÄúCompany‚Äù) today announced the pricing of an underwritten public offering of 28,000,000...",https://www.globenewswire.com/news-release/2019/12/11/1959278/32077/en/Marinus-Pharmaceuticals-Announces-Pricing-of-65-Million-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html,same
12/11/19,MRNS,38,31.85185185,36.2962963,gnw,Marinus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Concurrent Private Placement,"RADNOR, Pa., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (‚ÄúMarinus‚Äù or the ‚ÄúCompany‚Äù) today announced that it intends to offer and sell shares of its common stock...",https://www.globenewswire.com/news-release/2019/12/10/1958920/32077/en/Marinus-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock-and-Concurrent-Private-Placement.html,prev
12/13/19,SCPH,21,21.00456621,22.83105023,bw,scPharmaceuticals Inc. Announces Recent Progress on FUROSCIX¬Æ and Highlights Corporate Objectives,"scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patien...",http://www.businesswire.com/news/home/20191212005136/en/scPharmaceuticals-Inc.-Announces-Recent-Progress-on-FUROSCIX%C2%AE-and-Highlights-Corporate-Objectives,prev
12/16/19,MIRM,111,51.57894737,96.75438597,bw,Mirum Pharmaceuticals Completes Successful Pre-NDA Meeting with FDA for Maralixibat,"Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced the success...",http://www.businesswire.com/news/home/20191216005174/en/Mirum-Pharmaceuticals-Completes-Successful-Pre-NDA-Meeting-with-FDA-for-Maralixibat,same
12/19/19,ABEO,26.9,24.6882793,29.42643392,gnw,Abeona Therapeutics Announces Public Offering of Common Stock and Pre Funded Warrants,"NEW YORK and CLEVELAND, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that it intends to offer and...",https://www.globenewswire.com/news-release/2019/12/19/1963185/0/en/Abeona-Therapeutics-Announces-Public-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html,same
12/23/19,IDRA,24.2,23.37662338,29.2987013,gnw,Idera Pharmaceuticals Announces Private Placement Up To $97.7 Million,"EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an institutional...",https://www.globenewswire.com/news-release/2019/12/23/1964133/33448/en/Idera-Pharmaceuticals-Announces-Private-Placement-Up-To-97-7-Million.html,same
12/26/19,SBPH,-66.8,-53.84615385,0,gnw,Spring Bank Stops Dosing of Inarigivir Patients in Phase 2 Program,"HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of...",https://www.globenewswire.com/news-release/2019/12/26/1964523/0/en/Spring-Bank-Stops-Dosing-of-Inarigivir-Patients-in-Phase-2-Program.html,same
12/26/19,ACOR,43.2,40.30612245,41.83673469,bw,Acorda Therapeutics Completes Exchange of $276 Million of its 1.75% Convertible Senior Notes due June 2021; New Convertible Secured Notes Mature December 2024,"Acorda Therapeutics, Inc. (Nasdaq: ACOR) (‚ÄúAcorda‚Äù or the ‚ÄúCompany‚Äù) today announced it has successfully completed its previously announced private exchange of $276 million aggregate principal amount...",http://www.businesswire.com/news/home/20191226005042/en/Acorda-Therapeutics-Completes-Exchange-of-276-Million-of-its-1.75-Convertible-Senior-Notes-due-June-2021-New-Convertible-Secured-Notes-Mature-December-2024,same
12/27/19,MBOT,-20.7,-22.91666667,0.06875,gnw,Microbot Medical Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical...",https://www.globenewswire.com/news-release/2019/12/27/1964701/0/en/Microbot-Medical-Inc-Announces-10-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,same
12/27/19,MBOT,-20.7,-22.91666667,0.06875,gnw,Microbot Medical Inc. Announces Closing of $9.59 Million Registered Direct Offering of Common Stock,"HINGHAM, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq:MBOT) closed its previously announced registered direct offering of 912,858 shares of its common stock at a purchase...",https://www.globenewswire.com/news-release/2019/12/27/1964668/0/en/Microbot-Medical-Inc-Announces-Closing-of-9-59-Million-Registered-Direct-Offering-of-Common-Stock.html,same
12/27/19,MBOT,-20.7,-22.91666667,0.06875,gnw,Microbot Medical Inc. Announces $9.59 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"HINGHAM, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), a medical device company specializing in the design and development of transformational micro-robotic medical...",https://www.globenewswire.com/news-release/2019/12/26/1964522/0/en/Microbot-Medical-Inc-Announces-9-59-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,prev
12/27/19,ITRM,95.5,74.63235294,137.8676471,gnw,Iterum Therapeutics Announces Completion of Enrollment in Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infection,"DUBLIN, Ireland and CHICAGO, Dec. 26, 2019 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...",https://www.globenewswire.com/news-release/2019/12/26/1964576/0/en/Iterum-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-Clinical-Trial-of-Oral-Sulopenem-in-Uncomplicated-Urinary-Tract-Infection.html,prev
12/31/19,ONTX,-20.1,-26.21845502,9.805432479,gnw,"Onconova Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-The-Market","NEWTOWN, Pa., Dec. 31, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (‚ÄúOnconova‚Äù or the ‚ÄúCompany‚Äù), a Phase 3-stage biopharmaceutical company discovering and developing novel...",https://www.globenewswire.com/news-release/2019/12/31/1965391/0/en/Onconova-Therapeutics-Inc-Announces-10-Million-Registered-Direct-Offering-Priced-At-The-Market.html,same
12/31/19,BTAI,40.3,37.18309859,38.96713615,gnw,BioXcel Therapeutics Announces Initiation of Pivotal Phase 3 Studies of BXCL501 for Acute Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder,"NEW HAVEN, Conn., Dec. 30, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics (‚ÄúBTI‚Äù or ‚ÄúCompany‚Äù) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches...",https://www.globenewswire.com/news-release/2019/12/30/1964887/0/en/BioXcel-Therapeutics-Announces-Initiation-of-Pivotal-Phase-3-Studies-of-BXCL501-for-Acute-Treatment-of-Agitation-in-Patients-with-Schizophrenia-and-Bipolar-Disorder.html,prev
1/13/20,AQST,-34,-23.37434095,0.527240773,gnw,Aquestive Therapeutics Receives FDA Response to Citizen‚Äôs Petition,"WARREN, N.J., Jan. 12, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that...",https://www.globenewswire.com/news-release/2020/01/12/1969211/0/en/Aquestive-Therapeutics-Receives-FDA-Response-to-Citizen-s-Petition.html,prev
1/14/20,NK,-27.9,-25.1908397,0.975572519,bw,NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with N-803 IL-15 Fusion Protein,"NantKwest Inc., (Nasdaq: NK), a clinical-stage natural killer cell-based therapeutics company, today announced results from their Phase 1 trial investigating a novel, first-in-human immunotherapy cons...",http://www.businesswire.com/news/home/20200114005307/en/NantKwest-and-ImmunityBio-Announce-Complete-Response-in-Metastatic-Pancreatic-Cancer-in-the-First-Patient-to-Receive-PD-L1-Tumor-Targeted-Natural-Killer-Cells-PD-L1.t-haNK-Combined-with-N-803-IL-15-Fusion-Protein,same
1/22/20,CNCE,33,30.24875622,30.24875622,bw,"Concert Pharmaceuticals Announces Notice of Allowance for U.S. Patent Application Related to CTP-543, Lead Candidate for Treatment of Alopecia Areata","Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for patent application No. 16/098,338 related to CTP-5...",http://www.businesswire.com/news/home/20200122005425/en/Concert-Pharmaceuticals-Announces-Notice-of-Allowance-for-U.S.-Patent-Application-Related-to-CTP-543-Lead-Candidate-for-Treatment-of-Alopecia-Areata,same
1/22/20,TTPH,29.7,27.15231788,27.81456954,bw, Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market,"Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threateni...",http://www.businesswire.com/news/home/20200122005868/en/%C2%A0Tetraphase-Pharmaceuticals-Announces-17.5-Million-of-Financings-Priced-At-the-Market,same
1/24/20,MGEN,42.7,30.02680965,94.36997319,gnw,miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma at Two Upcoming Conferences,"BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific...",https://www.globenewswire.com/news-release/2020/01/23/1974267/31683/en/miRagen-Therapeutics-to-Present-New-Cobomarsen-Clinical-Trial-Data-for-Adult-T-Cell-Leukemia-Lymphoma-at-Two-Upcoming-Conferences.html,prev
1/28/20,STSA,29.9,29.35500254,31.64042661,gnw,Satsuma Pharmaceuticals Announces Publication of STS101 Phase 1 Clinical Trial Results in HEADACHE: The Journal of Head and Face Pain,"SOUTH SAN FRANCISCO, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today announced that Phase 1 trial results...",https://www.globenewswire.com/news-release/2020/01/28/1976390/0/en/Satsuma-Pharmaceuticals-Announces-Publication-of-STS101-Phase-1-Clinical-Trial-Results-in-HEADACHE-The-Journal-of-Head-and-Face-Pain.html,same
2/18/20,BLPH,168.4,44.96062992,88.66141732,gnw,Bellerophon Reports Positive Top-Line Data from an Ancillary Acute Hemodynamic Study of INOpulse¬Æ for Treatment of Pulmonary Hypertension Associated with Pulmonary Fibrosis,"WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (‚ÄúBellerophon‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biotherapeutics company, today announced positive...",https://www.globenewswire.com/news-release/2020/02/18/1986250/0/en/Bellerophon-Reports-Positive-Top-Line-Data-from-an-Ancillary-Acute-Hemodynamic-Study-of-INOpulse-for-Treatment-of-Pulmonary-Hypertension-Associated-with-Pulmonary-Fibrosis.html,same
2/25/20,IMV,-40,-36.78414097,4.845814978,bw,"IMV Inc. Announces Breakthrough Data from DeCidE1, its Ongoing Phase 2 Study of DPX-Survivac in Patients with Advanced Recurrent Ovarian Cancer","IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today reported updated results from DeCidE1, an ongoing Phase 2 study of its l...",http://www.businesswire.com/news/home/20200225005324/en/IMV-Inc.-Announces-Breakthrough-Data-from-DeCidE1-its-Ongoing-Phase-2-Study-of-DPX-Survivac-in-Patients-with-Advanced-Recurrent-Ovarian-Cancer,same
2/25/20,NMRD,76.3,72.56768819,151.1157394,bw,Nemaura Medical Plans Head-to-head Study with Major Glucose Monitoring System,"Nemaura Medical, Inc. (NASDAQ: NMRD) (‚ÄúNemaura‚Äù or the ‚ÄúCompany‚Äù), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing suga...",http://www.businesswire.com/news/home/20200225005660/en/Nemaura-Medical-Plans-Head-to-head-Study-with-Major-Glucose-Monitoring-System,same
2/26/20,APM,-53.5,-31.28205128,0,bw,Aptorum Group Announces Pricing of $10 Million Registered Direct Offering,"Aptorum Group Limited (NASDAQ: APM) (‚ÄúAptorum Group‚Äù), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced the pricing o...",http://www.businesswire.com/news/home/20200226005498/en/Aptorum-Group-Announces-Pricing-of-10-Million-Registered-Direct-Offering,same
2/28/20,TNXP,-37.6,-23.94366197,2.112676056,gnw,"Tonix Pharmaceuticals, Inc. Prices $16,005,000 Common Stock Offering Priced At-The-Market","NEW YORK, Feb. 28, 2020 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS, INC. (NASDAQ: TNXP) (‚ÄúTonix‚Äù or the ‚ÄúCompany‚Äù), a clinical-stage biopharmaceutical company, today announced it has entered into a...",https://www.globenewswire.com/news-release/2020/02/28/1992716/28908/en/Tonix-Pharmaceuticals-Inc-Prices-16-005-000-Common-Stock-Offering-Priced-At-The-Market.html,same
3/9/20,KALA,26.3,25.67353407,40.09508716,bw,Kala Pharmaceuticals Announces Statistically Significant Results for Primary and Key Secondary Endpoints in STRIDE 3 Clinical Trial Evaluating EYSUVIS‚Ñ¢ for Signs and Symptoms of Dry Eye Disease,"Kala Pharmaceuticals, Inc. (Kala) (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announce...",http://www.businesswire.com/news/home/20200309005294/en/Kala-Pharmaceuticals-Announces-Statistically-Significant-Results-for-Primary-and-Key-Secondary-Endpoints-in-STRIDE-3-Clinical-Trial-Evaluating-EYSUVIS%E2%84%A2-for-Signs-and-Symptoms-of-Dry-Eye-Disease,same
3/11/20,ASRT,25.7,20.79220779,22.96103896,gnw,Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024,"LAKE FOREST, Ill., March 11, 2020 (GLOBE NEWSWIRE) -- Assertio Therapeutics, Inc. (‚ÄúAssertio‚Äù or the ‚ÄúCompany‚Äù) (NASDAQ: ASRT), today announces that it has commenced cash tender offers (the...",https://www.globenewswire.com/news-release/2020/03/11/1998466/0/en/Assertio-Therapeutics-Announces-Offer-to-Purchase-All-of-Its-Issued-and-Outstanding-2-50-Senior-Convertible-Notes-Due-2021-and-5-00-Senior-Convertible-Notes-Due-2024.html,same
3/12/20,TENX,-36.5,-34.65346535,0,bw,Tenax Therapeutics Completes Enrollment in Phase 2 Pulmonary Hypertension Trial,"Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high...",http://www.businesswire.com/news/home/20200312005105/en/Tenax-Therapeutics-Completes-Enrollment-in-Phase-2-Pulmonary-Hypertension-Trial,same
3/12/20,TENX,-36.5,-34.65346535,0,bw,Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market,"Tenax Therapeutics, Inc. (Nasdaq: TENX) (‚ÄúTenax‚Äù or the ‚ÄúCompany‚Äù), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and p...",http://www.businesswire.com/news/home/20200312005139/en/Tenax-Therapeutics-Announces-2.75-Million-Registered-Direct-Offering-Priced-At-the-Market,same
3/12/20,SIEN,-23.4,-22.406639,2.282157676,gnw,Sientra Announces $60 Million Convertible Notes Investment from Deerfield Management,"SANTA BARBARA, Calif., March 11, 2020 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (‚ÄúSientra‚Äù or the ‚ÄúCompany‚Äù), a diversified medical aesthetics company, today announced that it has closed a...",https://www.globenewswire.com/news-release/2020/03/11/1999006/33599/en/Sientra-Announces-60-Million-Convertible-Notes-Investment-from-Deerfield-Management.html,prev
3/12/20,PSTV,-22.5,-22.53521127,0,gnw,Plus Therapeutics Welcomes Two New Directors,"AUSTIN, Texas, March 12, 2020 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the ‚ÄúCompany‚Äù), today announced that Dr. Robert Lenk and Mr. Howard Clowes will join the Company‚Äôs Board of...",https://www.globenewswire.com/news-release/2020/03/12/1999378/0/en/Plus-Therapeutics-Welcomes-Two-New-Directors.html,same
3/12/20,VRCA,-22.8,-27.5,0,gnw,Verrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank,"WEST CHESTER, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (‚ÄúVerrica‚Äù) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...",https://www.globenewswire.com/news-release/2020/03/11/1998602/0/en/Verrica-Pharmaceuticals-Secures-55-Million-in-Loan-Facilities-Led-by-Silicon-Valley-Bank.html,prev
3/18/20,ACER,-24.9,-24.9070632,1.617100372,gnw,Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA‚Äôs Office of New Drugs,"NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...",https://www.globenewswire.com/news-release/2020/03/18/2002958/0/en/Acer-Receives-Formal-Dispute-Resolution-Request-FDRR-Response-from-FDA-s-Office-of-New-Drugs.html,same
3/19/20,ACER,-31.2,-24.86486487,0,gnw,Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA‚Äôs Office of New Drugs,"NEWTON, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...",https://www.globenewswire.com/news-release/2020/03/18/2002958/0/en/Acer-Receives-Formal-Dispute-Resolution-Request-FDRR-Response-from-FDA-s-Office-of-New-Drugs.html,prev
3/19/20,RCKT,32.9,30.96446701,31.37055838,bw,Rocket Pharmaceuticals Announces Science Translational Medicine Publication of its Program in Danon Disease,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the...",http://www.businesswire.com/news/home/20200319005055/en/Rocket-Pharmaceuticals-Announces-Science-Translational-Medicine-Publication-of-its-Program-in-Danon-Disease,same
3/19/20,BLU,25.2,25.78125,30.234375,bw,BELLUS Health Announces Completion of Enrollment in Phase 2 RELIEF Trial of BLU-5937 for the Treatment of Refractory Chronic Cough,"BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (the ‚ÄúCompany‚Äù or ‚ÄúBELLUS Health‚Äù), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hyper...",http://www.businesswire.com/news/home/20200319005092/en/BELLUS-Health-Announces-Completion-of-Enrollment-in-Phase-2-RELIEF-Trial-of-BLU-5937-for-the-Treatment-of-Refractory-Chronic-Cough,same
3/24/20,BXRX,-48.1,-24.08026756,0,gnw,Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants,"MALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (‚ÄúBaudax‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...",https://www.globenewswire.com/news-release/2020/03/24/2005589/0/en/Baudax-Bio-Announces-Pricing-of-Public-Offering-of-Common-Stock-and-Warrants.html,same
3/24/20,BXRX,-48.1,-24.08026756,0,gnw,Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants,"MALVERN, Pa., March 23, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (‚ÄúBaudax‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today...",https://www.globenewswire.com/news-release/2020/03/23/2005075/0/en/Baudax-Bio-Announces-Proposed-Public-Offering-of-Common-Stock-and-Warrants.html,prev
3/24/20,IMAC,1025.2,147.5,147.5,gnw,IMAC Launches New Telehealth Options to Maintain Consistent Communications with Active Care Patients Choosing to ‚ÄúShelter in Place‚Äù,"BRENTWOOD, Tenn, March 24, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the ‚ÄúCompany‚Äù or ‚ÄúIMAC‚Äù), a provider of innovative medical advancements and care specializing in regenerative...",https://www.globenewswire.com/news-release/2020/03/24/2005464/0/en/IMAC-Launches-New-Telehealth-Options-to-Maintain-Consistent-Communications-with-Active-Care-Patients-Choosing-to-Shelter-in-Place.html,same
3/24/20,CAPR,51.7,43.08943089,76.42276423,gnw,Capricor Therapeutics to Host a Key Opinion Leader Call On Why Exosomes are Uniquely Suited for Vaccine Development,"LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for...",https://www.globenewswire.com/news-release/2020/03/24/2005458/0/en/Capricor-Therapeutics-to-Host-a-Key-Opinion-Leader-Call-On-Why-Exosomes-are-Uniquely-Suited-for-Vaccine-Development.html,same
3/25/20,IMAC,-54.9,-29.20634921,11.11111111,gnw,IMAC Launches New Telehealth Options to Maintain Consistent Communications with Active Care Patients Choosing to ‚ÄúShelter in Place‚Äù,"BRENTWOOD, Tenn, March 24, 2020 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (the ‚ÄúCompany‚Äù or ‚ÄúIMAC‚Äù), a provider of innovative medical advancements and care specializing in regenerative...",https://www.globenewswire.com/news-release/2020/03/24/2005464/0/en/IMAC-Launches-New-Telehealth-Options-to-Maintain-Consistent-Communications-with-Active-Care-Patients-Choosing-to-Shelter-in-Place.html,prev
3/26/20,BSGM,58.4,29.05263158,30.94736842,gnw,BioSig subsidiary NeuroClear acquires license for a broad-spectrum anti-viral agent that may treat COVID-19. Laboratory results demonstrate high level of activity against COVID-19 in cell culture,"Westport, CT, March 25, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (‚ÄúBioSig‚Äù or the ‚ÄúCompany‚Äù), a medical technology company commercializing a proprietary biomedical signal...",https://www.globenewswire.com/news-release/2020/03/25/2006132/22558/en/BioSig-subsidiary-NeuroClear-acquires-license-for-a-broad-spectrum-anti-viral-agent-that-may-treat-COVID-19-Laboratory-results-demonstrate-high-level-of-activity-against-COVID-19-i.html,prev
3/30/20,EYES,-51.3,-49.55752212,11.97345133,bw,"Second Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO","Second Sight Medical Products, Inc. (NASDAQ: EYES) (‚ÄúSecond Sight‚Äù or the ‚ÄúCompany‚Äù), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial...",http://www.businesswire.com/news/home/20200330005581/en/Second-Sight-Announces-Employee-Layoffs-Intent-to-Wind-Down-Operations-and-Appointment-of-Matthew-Pfeffer-as-Acting-CEO,same
3/30/20,STIM,28.3,25.92592593,40.7345679,gnw,Neuronetics Recognized as 2020 Top Neurology Device Provider,"Company acknowledged on Top 10 List by MedTech Outlook Magazine MALVERN, Pa., March 30, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company...",https://www.globenewswire.com/news-release/2020/03/30/2008259/0/en/Neuronetics-Recognized-as-2020-Top-Neurology-Device-Provider.html,same
3/31/20,SGBX,351.5,144.7368421,156.3157895,bw,"SG Blocks, Inc. and Transcend Onsite Care and Execute a Memorandum of Understanding","SG Blocks, Inc. (Nasdaq: SGBX) (‚ÄúSG Blocks‚Äù or the ‚ÄúCompany‚Äù), and Transcend Onsite Care, a cutting edge provider of on-site point of contact medical care, have executed a Memorandum of Understanding...",http://www.businesswire.com/news/home/20200331005238/en/SG-Blocks-Inc.-and-Transcend-Onsite-Care-and-Execute-a-Memorandum-of-Understanding,same
4/3/20,SRNE,22.8,25.88832487,36.04060914,gnw,SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS,"SAN DIEGO, April 02, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, ""Sorrento"") announced it has initiated the next phase of its collaboration with Celularity, Inc., a Warren,...",https://www.globenewswire.com/news-release/2020/04/02/2010998/0/en/SORRENTO-TO-PROVIDE-MANUFACTURING-SUPPORT-TO-CELULARITY-AS-CYNK-001-NK-CELL-TRIAL-FOR-COVID-19-BEGINS-ENROLLING-PATIENTS.html,prev
4/7/20,MNLO,-26.4,-31.33333333,0.66,gnw,Menlo Therapeutics Announces Results from Two Phase 3 Clinical Trials of Serlopitant for the Treatment of Pruritus Associated with Prurigo Nodularis,"BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (‚ÄúMenlo‚Äù or the ‚ÄúCompany‚Äù), a biopharmaceutical company focused on developing and commercializing...",https://www.globenewswire.com/news-release/2020/04/06/2012003/0/en/Menlo-Therapeutics-Announces-Results-from-Two-Phase-3-Clinical-Trials-of-Serlopitant-for-the-Treatment-of-Pruritus-Associated-with-Prurigo-Nodularis.html,prev
4/7/20,MOTS,28.3,20.16923077,30.75384615,gnw,Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its GEN2 Pure-Vu¬Æ System in Israel,"FORT LAUDERDALE, Fla., April 07, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (""Motus GI"" or the ""Company""), a medical technology company providing endoscopy solutions that...",https://www.globenewswire.com/news-release/2020/04/07/2012878/0/en/Motus-GI-Receives-Approval-from-the-Israeli-Ministry-of-Health-to-Initiate-Commercial-Sales-of-its-GEN2-Pure-Vu-System-in-Israel.html,same
4/8/20,MRSN,21.6,28.02721088,35.91836735,gnw,Mersana Therapeutics Raises $65 Million in Gross Proceeds Through its At-the-Market Facility,"CAMBRIDGE, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...",https://www.globenewswire.com/news-release/2020/04/08/2013249/0/en/Mersana-Therapeutics-Raises-65-Million-in-Gross-Proceeds-Through-its-At-the-Market-Facility.html,prev
4/29/20,CAPR,252.7,64.09266409,113.8996139,gnw,New Capricor Data Reports 100 Percent Survival in Critical COVID-19 Patients Treated with CAP-1002,"LOS ANGELES, April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (‚ÄúCapricor‚Äù) (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological...",https://www.globenewswire.com/news-release/2020/04/29/2024283/0/en/New-Capricor-Data-Reports-100-Percent-Survival-in-Critical-COVID-19-Patients-Treated-with-CAP-1002.html,same
4/29/20,CTMX,25.3,26.75893887,28.71972318,gnw,CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors,"SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of...",https://www.globenewswire.com/news-release/2020/04/28/2023646/37704/en/CytomX-Therapeutics-Appoints-Halley-E-Gilbert-to-Board-of-Directors.html,prev
4/29/20,AVEO,25.6,21.4953271,22.6635514,bw,AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program,"AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO‚Äôs vascular endothelial growth factor receptor tyro...",http://www.businesswire.com/news/home/20200429005779/en/AVEO-Oncology-to-Present-Final-Overall-Survival-Analysis-from-the-Phase-3-TIVO-3-Trial-of-Tivozanib-in-Renal-Cell-Carcinoma-at-the-ASCO-2020-Virtual-Scientific-Program,same
4/29/20,TXMD,78,54.38596491,61.42105263,bw,TherapeuticsMD Announces Issuance of First Orange Book Listable U.S. Patent for ANNOVERA¬Æ,"TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women‚Äôs healthcare company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent that covers the labeled in...",http://www.businesswire.com/news/home/20200429005171/en/TherapeuticsMD-Announces-Issuance-of-First-Orange-Book-Listable-U.S.-Patent-for-ANNOVERA%C2%AE,same
4/30/20,EYES,-36.7,-33.5,2,bw,Second Sight Medical Products Announces Pricing of Public Offering of Common Stock,"Second Sight Medical Products Inc. (NASDAQ: EYES), a developer, manufacturer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind in...",http://www.businesswire.com/news/home/20200430006073/en/Second-Sight-Medical-Products-Announces-Pricing-of-Public-Offering-of-Common-Stock,same
4/30/20,AVEO,25.8,26.74418605,50.96899225,bw,AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program,"AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO‚Äôs vascular endothelial growth factor receptor tyro...",http://www.businesswire.com/news/home/20200429005779/en/AVEO-Oncology-to-Present-Final-Overall-Survival-Analysis-from-the-Phase-3-TIVO-3-Trial-of-Tivozanib-in-Renal-Cell-Carcinoma-at-the-ASCO-2020-Virtual-Scientific-Program,prev
5/5/20,IMRA,31.6,34.90725127,34.90725127,gnw,Imara Announces Appointment of Stephen M. Migausky as General Counsel,"BOSTON, May 04, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...",https://www.globenewswire.com/news-release/2020/05/04/2026613/0/en/Imara-Announces-Appointment-of-Stephen-M-Migausky-as-General-Counsel.html,prev
5/6/20,RTTR,-31.2,-20.43399638,10.30741411,gnw,Leading Independent Proxy Advisory Firms Recommend Ritter Pharmaceuticals Shareholders Vote in Favor of its Merger and Each of the Merger Proposals,"LOS ANGELES, May 06, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (‚ÄúRitter Pharmaceuticals‚Äù or the ‚ÄúCompany‚Äù), today announced that Institutional Shareholder Services Inc....",https://www.globenewswire.com/news-release/2020/05/06/2028503/0/en/Leading-Independent-Proxy-Advisory-Firms-Recommend-Ritter-Pharmaceuticals-Shareholders-Vote-in-Favor-of-its-Merger-and-Each-of-the-Merger-Proposals.html,same
5/6/20,VAPO,34.5,23.71134021,27.09278351,bw,Vapotherm Announces Pricing of Public Offering of Common Stock,"Vapotherm, Inc. (NYSE: VAPO) (‚ÄúVapotherm‚Äù), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI¬Æ Technology products that are used to treat p...",http://www.businesswire.com/news/home/20200506006153/en/Vapotherm-Announces-Pricing-of-Public-Offering-of-Common-Stock,same
5/6/20,VAPO,34.5,23.71134021,27.09278351,bw,Vapotherm Announces Proposed Public Offering of Common Stock,"Vapotherm, Inc. (NYSE:VAPO) (‚ÄúVapotherm‚Äù), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI¬Æ Technology products that are used to treat pa...",http://www.businesswire.com/news/home/20200506006032/en/Vapotherm-Announces-Proposed-Public-Offering-of-Common-Stock,same
5/12/20,RTTR,32.3,32.5013764,37.63993393,gnw,Ritter Pharmaceuticals Regains Compliance with Nasdaq‚Äôs Stockholders‚Äô Equity Requirement for Continued Listing,"LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (‚ÄúRitter Pharmaceuticals‚Äù or the ‚ÄúCompany‚Äù), today announced that it has received written notice from the...",https://www.globenewswire.com/news-release/2020/05/11/2031044/0/en/Ritter-Pharmaceuticals-Regains-Compliance-with-Nasdaq-s-Stockholders-Equity-Requirement-for-Continued-Listing.html,prev
5/15/20,SEEL,31.1,22.78481013,25.3164557,gnw,Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors,"NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...",https://www.globenewswire.com/news-release/2020/05/15/2034331/14295/en/Seelos-Therapeutics-Announces-Appointment-of-Judith-Dunn-to-the-Board-of-Directors.html,same
5/15/20,SEEL,31.1,22.78481013,25.3164557,gnw,Seelos Therapeutics Receives Rare Pediatric Disease Designation for SLS-005 (Trehalose) in Sanfilippo Syndrome,"NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...",https://www.globenewswire.com/news-release/2020/05/15/2034166/14295/en/Seelos-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-for-SLS-005-Trehalose-in-Sanfilippo-Syndrome.html,same
5/20/20,ATOS,25.7,25,52.27272727,gnw,Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture,"SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...",https://www.globenewswire.com/news-release/2020/05/20/2036465/0/en/Atossa-Therapeutics-Announces-Successful-In-vitro-Testing-Results-of-COVID-19-Drug-AT-H201-Inhibits-SARS-CoV-2-Infectivity-of-VERO-Cells-in-Laboratory-Culture.html,same
5/20/20,ATRA,28.9,25.1754386,31.22807018,bw,Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 European Academy of Neurology (EAN) Virtual Congress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases including soli...",http://www.businesswire.com/news/home/20200519005372/en/Atara-Biotherapeutics-to-Present-Late-Breaking-ATA188-Data-in-Progressive-Multiple-Sclerosis-at-2020-European-Academy-of-Neurology-EAN-Virtual-Congress,prev
5/22/20,XERS,28,26.08695652,27.17391304,bw,Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation platforms to develop and commercialize ready-to-use injectable and infusible drug formul...",http://www.businesswire.com/news/home/20200522005045/en/Xeris-Pharmaceuticals-Announces-Positive-Findings-From-the-Outpatient-Portion-of-a-Phase-2-Proof-of-Concept-Study-of-Its-Developmental-Ready-to-Use-RTU-Glucagon-in-Patients-at-Risk-of-Postprandial-Hypoglycemia-Following-Bariatric-Surgery,same
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Announces Pricing of $175.5 Million Public Offering,"Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i...",http://www.businesswire.com/news/home/20200526005915/en/Atara-Biotherapeutics-Announces-Pricing-of-175.5-Million-Public-Offering,same
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants,"Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases i...",http://www.businesswire.com/news/home/20200526005809/en/Atara-Biotherapeutics-Announces-Proposed-Offering-of-Common-Stock-and-Pre-Funded-Warrants,same
5/26/20,ATRA,-23.6,-27.38935215,1.154586273,bw,Atara Biotherapeutics Presents Data Demonstrating Safety & Sustained Disability Improvement at 12 Months with ATA188 in Patients with Progressive Multiple Sclerosis in Late-Breaking e-Poster at the 2020 European Academy of Neurology Virtual Congress,"Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including sol...",http://www.businesswire.com/news/home/20200526005266/en/Atara-Biotherapeutics-Presents-Data-Demonstrating-Safety-Sustained-Disability-Improvement-at-12-Months-with-ATA188-in-Patients-with-Progressive-Multiple-Sclerosis-in-Late-Breaking-e-Poster-at-the-2020-European-Academy-of-Neurology-Virtual-Congress,same
5/27/20,MGEN,24.5,22.37258854,31.01065361,gnw,miRagen to Present at the Jefferies 2020 Virtual Global Healthcare Conference,"BOULDER, Colo., May 26, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted...",https://www.globenewswire.com/news-release/2020/05/26/2038555/31683/en/miRagen-to-Present-at-the-Jefferies-2020-Virtual-Global-Healthcare-Conference.html,prev
5/27/20,NK,39.1,37.56805808,51.36116153,bw,"ImmunityBio & NantKwest Sign COVID-19 Joint Development, Manufacturing and Marketing Agreement; ImmunityBio Selected for ‚ÄòOperation Warp Speed‚Äô to Develop Novel Adenovirus COVID-19 Vaccine ","NantKwest, Inc. (Nasdaq: NK), a clinical-stage, natural killer cell-based therapeutics company, and ImmunityBio, a privately-held immunotherapy company, today announced ImmunityBio has been selected t...",http://www.businesswire.com/news/home/20200527005680/en/ImmunityBio-NantKwest-Sign-COVID-19-Joint-Development-Manufacturing-and-Marketing-Agreement-ImmunityBio-Selected-for-%E2%80%98Operation-Warp-Speed%E2%80%99-to-Develop-Novel-Adenovirus-COVID-19-Vaccine%C2%A0,same
5/29/20,NBRV,33.9,30.07759014,36.9237791,gnw,Nabriva Therapeutics Announces $38 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 29, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of...",https://www.globenewswire.com/news-release/2020/05/29/2041207/37424/en/Nabriva-Therapeutics-Announces-38-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,same
5/29/20,ZNTL,26.4,25.64966314,26.15495669,gnw,Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference,"NEW YORK and SAN DIEGO, May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on developing clinically differentiated,...",https://www.globenewswire.com/news-release/2020/05/28/2040545/0/en/Zentalis-Pharmaceuticals-to-Participate-in-Jefferies-Virtual-Healthcare-Conference.html,prev
5/29/20,ZNTL,26.4,25.64966314,26.15495669,gnw,Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies,"NEW YORK, SAN DIEGO and DURHAM, N.C., May 28, 2020 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) and Tavros Therapeutics, Inc., today announced a strategic collaboration to apply...",https://www.globenewswire.com/news-release/2020/05/28/2040075/0/en/Zentalis-Pharmaceuticals-and-Tavros-Therapeutics-Announce-Strategic-Platform-Collaboration-to-Discover-Next-Generation-Targeted-Small-Molecule-Therapies.html,prev
6/4/20,TMDI,467.1,130.8823529,130.8823529,bw,Titan Medical Announces Development and License Agreements With Medtronic and Senior Secured Loan,"Titan Medical Inc. (‚ÄúTitan‚Äù or ‚ÄúTitan Medical‚Äù) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of single-port robotic surgical technologies, announces that i...",http://www.businesswire.com/news/home/20200604005323/en/Titan-Medical-Announces-Development-and-License-Agreements-With-Medtronic-and-Senior-Secured-Loan,same
6/15/20,CLDX,37.3,45.31886024,50.74626866,gnw,Celldex Therapeutics Announces Proposed Public Offering of Common Stock,"HAMPTON, N.J., June 15, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (‚ÄúCelldex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: CLDX), today announced that it is proposing to offer and sell, subject to market...",https://www.globenewswire.com/news-release/2020/06/15/2048347/24180/en/Celldex-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html,same
6/19/20,CLDX,29.2,28.94230769,33.75,gnw,Celldex Therapeutics Announces Closing of $150.0 Million Public Offering of Common Stock Including Full Exercise of Underwriters‚Äô Option to Purchase Additional Shares,"HAMPTON, N.J., June 18, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (‚ÄúCelldex‚Äù or the ‚ÄúCompany‚Äù) (Nasdaq: CLDX), today announced the closing of its underwritten public offering of 15,384,614...",https://www.globenewswire.com/news-release/2020/06/18/2050270/24180/en/Celldex-Therapeutics-Announces-Closing-of-150-0-Million-Public-Offering-of-Common-Stock-Including-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html,prev
6/25/20,XERS,-48.8,-34.14043584,0,bw,Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",http://www.businesswire.com/news/home/20200625005937/en/Xeris-Pharmaceuticals-Announces-Pricing-of-Public-Offerings-of-20-Million-of-Common-Stock-and-75-Million-of-5.00-Convertible-Senior-Notes-Due-2025,same
6/25/20,XERS,-48.8,-34.14043584,0,bw,Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes,"Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formula...",http://www.businesswire.com/news/home/20200624005775/en/Xeris-Pharmaceuticals-Announces-Proposed-Public-Offerings-of-20-Million-of-Common-Stock-and-60-Million-of-Convertible-Senior-Notes,prev
6/25/20,EKSO,135.3,31.20503597,57.55395684,gnw,Ekso Bionics¬Æ Receives FDA Clearance to Market its EksoNR‚Ñ¢ Robotic Exoskeleton for Use with Acquired Brain Injury Patients,"RICHMOND, Calif., June 25, 2020 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the ‚ÄúCompany‚Äù), an industry leader in exoskeleton technology for medical and industrial use, today...",https://www.globenewswire.com/news-release/2020/06/25/2053400/29945/en/Ekso-Bionics-Receives-FDA-Clearance-to-Market-its-EksoNR-Robotic-Exoskeleton-for-Use-with-Acquired-Brain-Injury-Patients.html,same
7/15/20,STIM,38.9,24.43438914,64.70588235,gnw,Neuronetics Announces the Appointment of Keith J. Sullivan as President and Chief Executive Officer,"MALVERN, Pa., July 14, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on improving the lives of patients who suffer from psychiatric...",https://www.globenewswire.com/news-release/2020/07/14/2062184/0/en/Neuronetics-Announces-the-Appointment-of-Keith-J-Sullivan-as-President-and-Chief-Executive-Officer.html,prev
7/27/20,VTVT,27.9,21.13821138,25.6097561,gnw,vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference,"HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International...",https://www.globenewswire.com/news-release/2020/07/27/2067814/0/en/vTv-Therapeutics-to-Present-Additional-Clinical-Data-from-the-STEADFAST-Study-of-Azeliragon-at-the-Virtual-Alzheimer-s-Association-International-Conference.html,same
8/4/20,PRPO,25.2,29.73856209,63.39869281,gnw,Precipio Launches Covid-19 Antibody Test in its CLIA laboratory,"NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has completed the internal validation of the FDA-approved COVID-19...",https://www.globenewswire.com/news-release/2020/08/04/2072650/0/en/Precipio-Launches-Covid-19-Antibody-Test-in-its-CLIA-laboratory.html,same
8/6/20,CWBR,23.5,23.81407005,32.44823677,gnw,CohBar Presents New Antifibrotic Data at the American Thoracic Society‚Äôs Virtual 2020 Conference,"MENLO PARK, Calif., Aug. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...",https://www.globenewswire.com/news-release/2020/08/05/2073348/0/en/CohBar-Presents-New-Antifibrotic-Data-at-the-American-Thoracic-Society-s-Virtual-2020-Conference.html,prev
8/13/20,MBOT,20.8,20.57488654,23.14674735,gnw,Microbot Medical to Share Current Results of a Feasibility Animal Study Utilizing the LIBERTY Robotic System,"HINGHAM, Mass., Aug. 13, 2020 (GLOBE NEWSWIRE) -- At the upcoming Needham Virtual Med Tech & Diagnostics Conference, being held on Monday, August 17, 2020, Microbot Medical Inc. (Nasdaq: MBOT),...",https://www.globenewswire.com/news-release/2020/08/13/2077955/0/en/Microbot-Medical-to-Share-Current-Results-of-a-Feasibility-Animal-Study-Utilizing-the-LIBERTY-Robotic-System.html,same
8/17/20,CKPT,21.1,20.53140097,22.22222222,gnw,"Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020","NEW YORK, Aug. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (‚ÄúCheckpoint‚Äù) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F....",https://www.globenewswire.com/news-release/2020/08/17/2079189/36989/en/Checkpoint-Therapeutics-to-Present-at-Virtual-Corporate-Access-Summit-Hosted-by-B-Riley-FBR-on-Wednesday-August-19-2020.html,same
8/24/20,ODT,-45.3,-25.21419829,1.754385965,bw,"Odonate Therapeutics Announces Positive Top-line Results from CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer","Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced...",http://www.businesswire.com/news/home/20200824005197/en/Odonate-Therapeutics-Announces-Positive-Top-line-Results-from-CONTESSA-a-Phase-3-Study-of-Tesetaxel-in-Patients-with-Metastatic-Breast-Cancer,same
9/1/20,TCON,27.5,20.5,29,gnw,TRACON Pharmaceuticals Announces Additional $5.0 Million Private Placement,"SAN DIEGO, Aug. 31, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted...",https://www.globenewswire.com/news-release/2020/08/31/2086130/10391/en/TRACON-Pharmaceuticals-Announces-Additional-5-0-Million-Private-Placement.html,prev
9/2/20,SNSS,-37,-35.15384615,2.115384615,gnw,Sunesis Pharmaceuticals Announces 1-for-10 Reverse Stock Split,"SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has filed a Certificate of Amendment to its Amended and Restated...",https://www.globenewswire.com/news-release/2020/09/02/2087934/14761/en/Sunesis-Pharmaceuticals-Announces-1-for-10-Reverse-Stock-Split.html,same
9/28/20,ABEO,-41.4,-24.82758621,0.689655172,gnw,Abeona Therapeutics Announces Leadership and Board Transitions,"NEW YORK and CLEVELAND, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced changes in its executive...",https://www.globenewswire.com/news-release/2020/09/28/2099961/0/en/Abeona-Therapeutics-Announces-Leadership-and-Board-Transitions.html,same
10/1/20,CHFS,28.6,27.11864407,31.38983051,gnw,CHF Solutions Initiatives at HFSA 24th Annual Scientific Meeting Highlight Aquadex Therapy Performance in Heart Failure,"EDEN PRAIRIE, Minn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today...",https://www.globenewswire.com/news-release/2020/09/30/2101315/26106/en/CHF-Solutions-Initiatives-at-HFSA-24th-Annual-Scientific-Meeting-Highlight-Aquadex-Therapy-Performance-in-Heart-Failure.html,prev
10/20/20,ALRN,31.6,27.93296089,37.98882682,gnw,Aileron Therapeutics to Host Conference Call to Discuss Results from Phase 1b Proof-of-Concept Study of Chemoprotective Therapy ALRN-6924 Being Presented at EORTC-NCI-AACR Annual Symposium,"WATERTOWN, Mass., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that it will host a conference call and live webcast to discuss results from a Phase 1b...",https://www.globenewswire.com/news-release/2020/10/20/2111157/28652/en/Aileron-Therapeutics-to-Host-Conference-Call-to-Discuss-Results-from-Phase-1b-Proof-of-Concept-Study-of-Chemoprotective-Therapy-ALRN-6924-Being-Presented-at-EORTC-NCI-AACR-Annual-S.html,same
11/6/20,ASMB,-69.4,-22.6984127,0.793650794,gnw,Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting...",https://www.globenewswire.com/news-release/2020/11/06/2122215/16259/en/Assembly-Biosciences-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,same
12/8/20,INFI,29.4,26.48401827,29.6803653,bw,Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium,"Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple...",http://www.businesswire.com/news/home/20201207005253/en/Infinity-Pharmaceuticals-Announces-Conference-Call-for-the-2020-San-Antonio-Breast-Cancer-Symposium,prev
12/9/20,PBLA,23.8,26.66666667,27.53333333,gnw,"Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer","MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of...",https://www.globenewswire.com/news-release/2020/12/08/2141279/37414/en/Panbela-Therapeutics-Inc-Completes-Enrollment-in-its-Phase-1b-Trial-Investigating-SBP-101-Combination-Therapy-for-First-Line-Metastatic-Pancreatic-Cancer.html,prev
12/9/20,ONCT,24,24.75247525,42.37623762,gnw,Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering,"SAN DIEGO, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today...",https://www.globenewswire.com/news-release/2020/12/09/2142684/0/en/Oncternal-Therapeutics-Announces-40-0-Million-Bought-Deal-Offering.html,same
12/9/20,RCKT,83.4,28.25327511,39.62882096,bw,Rocket Pharmaceuticals Prices Upsized Public Offering of Common Stock,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the...",http://www.businesswire.com/news/home/20201209006084/en/Rocket-Pharmaceuticals-Prices-Upsized-Public-Offering-of-Common-Stock,same
12/9/20,RCKT,83.4,28.25327511,39.62882096,bw,Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock,"Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces tha...",http://www.businesswire.com/news/home/20201209005516/en/Rocket-Pharmaceuticals-Announces-Proposed-Public-Offering-of-Common-Stock,same
12/9/20,RCKT,83.4,28.25327511,39.62882096,bw,"Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease","Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (‚ÄúRocket‚Äù), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces pre...",http://www.businesswire.com/news/home/20201208006068/en/Rocket-Pharmaceuticals-Announces-Positive-Gene-Expression-Clinical-Biomarker-and-Preliminary-Functional-Data-from-Phase-1-Trial-of-RP-A501-for-the-Treatment-of-Danon-Disease,prev
12/15/20,SRTS,25.7,26.76056338,26.76056338,gnw,Sensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100‚Ñ¢ Systems,"BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and...",https://www.globenewswire.com/news-release/2020/12/15/2145317/0/en/Sensus-Healthcare-Engages-Ekpac-Healthcare-Ltd-as-New-Exclusive-Distributor-in-China-for-SRT-100-Systems.html,same
12/17/20,ATXI,47.7,39.03061225,59.43877551,gnw,Avenue Therapeutics Provides Regulatory Update for IV Tramadol,"NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a...",https://www.globenewswire.com/news-release/2020/12/17/2146835/0/en/Avenue-Therapeutics-Provides-Regulatory-Update-for-IV-Tramadol.html,same
12/21/20,NK,56.1,23.09820194,36.6989396,bw,"ImmunityBio and NantKwest to Merge, Creating a Leading Immunotherapy and Cell Therapy Company","ImmunityBio, a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced they have entered into an agree...",http://www.businesswire.com/news/home/20201221005280/en/ImmunityBio-and-NantKwest-to-Merge-Creating-a-Leading-Immunotherapy-and-Cell-Therapy-Company,same
12/22/20,EAR,22,22.00463255,23.2259423,gnw,Eargo to Present at 39th Annual J.P. Morgan Healthcare Conference,"SAN JOSE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Eargo, Inc. (Nasdaq: EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced it...",https://www.globenewswire.com/news-release/2020/12/21/2148981/0/en/Eargo-to-Present-at-39th-Annual-J-P-Morgan-Healthcare-Conference.html,prev
12/22/20,CYCC,49.5,42.22222222,57.11111111,gnw,"Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of Directors","BERKELEY HEIGHTS, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; ""Cyclacel"" or the ""Company""), a biopharmaceutical company developing innovative...",https://www.globenewswire.com/news-release/2020/12/21/2148507/10564/en/Cyclacel-Pharmaceuticals-Announces-That-Brian-Schwartz-M-D-Was-Elected-to-Its-Board-of-Directors.html,prev
1/4/21,EYPT,36.9,30.57971015,35.67391304,gnw,EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension Therapeutics,"WATERTOWN, Mass., Jan. 03, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic...",https://www.globenewswire.com/news-release/2021/01/04/2152262/0/en/EyePoint-Pharmaceuticals-Announces-15-7-Million-Equity-Investment-by-Asia-Partner-Ocumension-Therapeutics.html,prev
1/8/21,APDN,104.9,103.8528897,116.2854641,bw,U.S. FDA Lists Applied DNA‚Äôs Linea‚Ñ¢ COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7),"Applied DNA Sciences, Inc. (NASDAQ: APDN) (the ‚ÄúCompany‚Äù), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) publish...",http://www.businesswire.com/news/home/20210108005522/en/U.S.-FDA-Lists-Applied-DNA%E2%80%99s-Linea%E2%84%A2-COVID-19-Assay-Kit-as-1-of-Only-2-EUA-Authorized-Tests-Able-to-Detect-S-Gene-Mutation-Found-in-SARS-CoV-2-U.K.-Variant-B.1.1.7,same
1/11/21,DFFN,34,31.31313131,36.36363636,gnw,Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference,"CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (‚ÄúDiffusion‚Äù or ‚Äúthe Company‚Äù), today announced that the Company is participating in the...",https://www.globenewswire.com/news-release/2021/01/11/2156163/0/en/Diffusion-Pharmaceuticals-to-Participate-in-H-C-Wainwright-BioConnect-2021-Conference.html,same
1/14/21,LXRX,105.4,90.75829384,122.7488152,gnw,Lexicon Pharmaceuticals Provides Regulatory Update on Sotagliflozin in Heart Failure,"THE WOODLANDS, Texas, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has received U.S. Food and Drug Administration (FDA) regulatory feedback...",https://www.globenewswire.com/news-release/2021/01/14/2158603/0/en/Lexicon-Pharmaceuticals-Provides-Regulatory-Update-on-Sotagliflozin-in-Heart-Failure.html,same
1/19/21,ACRS,220.2,34.02135231,41.99288256,gnw,Aclaris Announces Proposed Public Offering of Common Stock,"WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...",https://www.globenewswire.com/news-release/2021/01/19/2161003/37216/en/Aclaris-Announces-Proposed-Public-Offering-of-Common-Stock.html,same
1/20/21,TLSA,49.2,35.14285714,51.14285714,gnw,"Tiziana Life Sciences plc (""Tiziana"" or the ""Company"") - AIM Delisting and Admission to the Standard Listing Segment of Main Market","NEW YORK and LONDON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (‚ÄúTiziana‚Äù or the ‚ÄúCompany‚Äù), a biotechnology company focused on innovative therapeutics...",https://www.globenewswire.com/news-release/2021/01/20/2161151/0/en/Tiziana-Life-Sciences-plc-Tiziana-or-the-Company-AIM-Delisting-and-Admission-to-the-Standard-Listing-Segment-of-Main-Market.html,same
1/20/21,ADMP,77.6,39.10505837,61.47859922,gnw,Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19,"SAN DIEGO, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (‚ÄúAdamis‚Äù) announced today the submission of an Investigational New Drug (IND) to FDA for the...",https://www.globenewswire.com/news-release/2021/01/20/2161463/32832/en/Adamis-Pharmaceuticals-Announces-IND-Submission-to-FDA-for-Tempol-for-the-Treatment-of-COVID-19.html,same
1/21/21,DYN,-25.6,-20.18038332,0.601277715,gnw,Dyne Therapeutics Announces Pricing of $168 Million Public Offering,"WALTHAM, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living...",https://www.globenewswire.com/news-release/2021/01/21/2161815/0/en/Dyne-Therapeutics-Announces-Pricing-of-168-Million-Public-Offering.html,prev
1/21/21,ADTX,45.6,22.65582131,117.2299151,gnw,AditxtScore‚Ñ¢ Immune Monitoring Service Will be Operational on February 1st,"Company Plans to Offer Service through Channel Partners Mountain View, CA, Jan. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aditx Therapeutics, Inc. (Aditxt) (the ‚ÄúCompany‚Äù) (Nasdaq: ADTX),...",https://www.globenewswire.com/news-release/2021/01/21/2162117/0/en/AditxtScore-Immune-Monitoring-Service-Will-be-Operational-on-February-1st.html,same
2/1/21,APLT,21.3,22.99128751,37.99612778,gnw,Applied Therapeutics Announces Restart of Pediatric Galactosemia Study,"FDA Clinical Hold Lifted NEW YORK, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug...",https://www.globenewswire.com/news-release/2021/02/01/2167143/0/en/Applied-Therapeutics-Announces-Restart-of-Pediatric-Galactosemia-Study.html,same
2/8/21,SIEN,36.6,33.51157156,49.21881527,gnw,Sientra Commences Public Offering of Common Stock,"SANTA BARBARA, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (‚ÄúSientra‚Äù or the ‚ÄúCompany‚Äù), a medical aesthetics company uniquely focused on plastic surgeons, today announced...",https://www.globenewswire.com/news-release/2021/02/08/2171689/33599/en/Sientra-Commences-Public-Offering-of-Common-Stock.html,same
2/8/21,EKSO,25.3,22.14953271,40,gnw,Ekso Bionics Announces $10 Million Bought Deal Offering Of Common Stock,"RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (‚ÄúEkso Bionics‚Äù), an industry leader in exoskeleton technology for medical and industrial use, today...",https://www.globenewswire.com/news-release/2021/02/08/2171754/29945/en/Ekso-Bionics-Announces-10-Million-Bought-Deal-Offering-Of-Common-Stock.html,same
2/9/21,RMTI,30.4,26.97368421,30.2631579,gnw,Rockwell Medical Announces U.S. Availability of Triferic¬Æ AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis,"WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management...",https://www.globenewswire.com/news-release/2021/02/09/2172048/30312/en/Rockwell-Medical-Announces-U-S-Availability-of-Triferic-AVNU-for-Replacement-of-Iron-and-Maintenance-of-Hemoglobin-in-Patients-on-Hemodialysis.html,same
2/10/21,ITRM,20.3,24.65753425,27.85388128,gnw,Iterum Therapeutics plc Announces Exercise of Underwriter‚Äôs Option to Purchase Additional Ordinary Shares,"DUBLIN, Ireland and CHICAGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...",https://www.globenewswire.com/news-release/2021/02/10/2173645/0/en/Iterum-Therapeutics-plc-Announces-Exercise-of-Underwriter-s-Option-to-Purchase-Additional-Ordinary-Shares.html,same
2/10/21,ITRM,20.3,24.65753425,27.85388128,gnw,Iterum Therapeutics plc Announces $35.0 Million Registered Direct Offering of Ordinary Shares Priced At-the-Market under Nasdaq Rules,"DUBLIN, Ireland and CHICAGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...",https://www.globenewswire.com/news-release/2021/02/10/2172766/0/en/Iterum-Therapeutics-plc-Announces-35-0-Million-Registered-Direct-Offering-of-Ordinary-Shares-Priced-At-the-Market-under-Nasdaq-Rules.html,prev
2/16/21,PAVM,28.3,23.35164835,31.04395604,gnw,First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed‚Äôs CarpX¬Æ Device,"NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ‚ÄúCompany‚Äù or ‚ÄúPAVmed‚Äù), a highly differentiated, multi-product, commercial-stage medical technology company, today...",https://www.globenewswire.com/news-release/2021/02/16/2176335/0/en/First-U-S-Patient-Undergoes-Successful-Minimally-Invasive-Carpal-Tunnel-Release-Using-PAVmed-s-CarpX-Device.html,same
2/17/21,PCSA,33.2,27.33727811,36.09467456,gnw,Processa Pharmaceuticals Announces $10.2 Million Strategic Financing,"Strengthened Financial Position Supports Execution Through 2023 HANOVER, MD., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (‚ÄúProcessa‚Äù or the ‚ÄúCompany‚Äù), a...",https://www.globenewswire.com/news-release/2021/02/17/2177085/0/en/Processa-Pharmaceuticals-Announces-10-2-Million-Strategic-Financing.html,same
2/22/21,PAVM,21.4,37.71712159,39.70223325,gnw,PAVmed Announces Proposed Public Offering of Common Stock,"NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the ‚ÄúCompany‚Äù or ‚ÄúPAVmed‚Äù), a highly differentiated, multi-product, commercial-stage medical device company, today...",https://www.globenewswire.com/news-release/2021/02/22/2179943/0/en/PAVmed-Announces-Proposed-Public-Offering-of-Common-Stock.html,same
3/5/21,EYES,304.9,152.8384279,331.8777293,bw,"Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System","Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, to...",http://www.businesswire.com/news/home/20210305005098/en/Second-Sight-Medical-Products-Inc.-Receives-FDA-Approval-for-the-Argus-2s-Retinal-Prosthesis-System,same
3/10/21,AVEO,89.1,85.88807786,86.98296837,bw,AVEO Oncology Announces U.S. FDA Approval of FOTIVDA¬Æ (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA¬Æ (tivozanib) for the treatment of adults with relapsed or refractory advanced renal c...,http://www.businesswire.com/news/home/20210310005893/en/AVEO-Oncology-Announces-U.S.-FDA-Approval-of-FOTIVDA%C2%AE-tivozanib-for-the-Treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Advanced-Renal-Cell-Carcinoma,same
3/11/21,AVEO,-22.3,-33.31460674,2.471910112,bw,AVEO Oncology Announces U.S. FDA Approval of FOTIVDA¬Æ (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma,AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA¬Æ (tivozanib) for the treatment of adults with relapsed or refractory advanced renal c...,http://www.businesswire.com/news/home/20210310005893/en/AVEO-Oncology-Announces-U.S.-FDA-Approval-of-FOTIVDA%C2%AE-tivozanib-for-the-Treatment-of-Adult-Patients-with-Relapsed-or-Refractory-Advanced-Renal-Cell-Carcinoma,prev
3/15/21,RUBY,84.4,69.12339475,116.1362367,gnw,Rubius Therapeutics Announces Proposed Public Offering of Common Stock,"CAMBRIDGE, Mass., March 15, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ: RUBY) (‚ÄúRubius‚Äù), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells...",https://www.globenewswire.com/news-release/2021/03/15/2193194/0/en/Rubius-Therapeutics-Announces-Proposed-Public-Offering-of-Common-Stock.html,same
3/19/21,CLVS,47.7,22.8125,39.84375,bw,Clovis Oncology‚Äôs Rubraca¬Æ (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation,"Clovis Oncology, Inc. (NASDAQ: CLVS) announced that the first presentation of data from the randomized, Phase 3 ARIEL4 study of Rubraca¬Æ (rucaparib) will take place today in an oral presentation at th...",http://www.businesswire.com/news/home/20210319005072/en/Clovis-Oncology%E2%80%99s-Rubraca%C2%AE-rucaparib-Significantly-Improves-Progression-Free-Survival-versus-Chemotherapy-in-Patients-with-Later-line-Ovarian-Cancer-Associated-with-a-BRCA-Mutation,same
